Teligent (TLGTQ) 10-K16 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 10, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	IGI LABORATORIES, INC
Entity Central Index Key	352998
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Trading Symbol	IG
Entity Common Stock, Shares Outstanding		52,827,453
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$158.80

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$158,883	$2,101
Accounts receivable, net	14,366	4,947
Inventories	2,784	2,869
Prepaid expenses and other receivables	1,185	641
Total current assets	177,218	10,558
Property, plant and equipment, net	3,262	2,623
Product acquisition costs, net	10,604	1,766
Debt issuance costs, net	5,132	69
Other	862	411
Total assets	197,078	15,427
Current liabilities:
Accounts payable	1,643	1,523
Accrued expenses	5,141	2,915
Payable for product acquisition costs	6,000	0
Deferred income, current	87	768
Capital lease obligation, current	131	15
Total current liabilities	13,002	5,221
Convertible 3.75% senior notes, net of debt discount (face of $143,750)	100,311	0
Fair value of derivative liability - convertible 3.75% senior notes	41,400	0
Note payable, bank	3,160	3,000
Other long term liabilities	71	15
Total liabilities	157,944	8,236
Stockholdersâ€™ equity:
Common stock, $0.01 par value, 60,000,000 shares authorized; 52,819,787 and 46,748,575 shares issued and outstanding as of December 31, 2014 and December 31, 2013, respectively	548	487
Additional paid-in capital	78,172	51,541
Accumulated deficit	-39,586	-44,837
Total stockholders' equity	39,134	7,191
Total liabilities and stockholders' equity	197,078	15,427
Series A Preferred Stock [Member]
Stockholdersâ€™ equity:
Convertible Preferred Stock	0	0
Series C Preferred Stock [Member]
Stockholdersâ€™ equity:
Convertible Preferred Stock	$0	$0

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	1,000,000
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	52,819,787	46,748,575
Common stock, shares outstanding	52,819,787	46,748,575
Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.75%
Debt Instrument, Face Amount	$143,750
Series A Preferred Stock [Member]
Preferred Stock, par value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Shares Authorized	100	100
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series C Preferred Stock [Member]
Preferred Stock, par value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Shares Authorized	1,550	1,550
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product sales, net	$32,104	$16,981	$6,545
Research and development income	1,490	1,094	1,931
Licensing, royalty and other revenue	146	149	87
Total revenues	33,740	18,224	8,563
Costs and Expenses:
Cost of revenues	16,948	12,079	5,787
Selling, general and administrative expenses	5,976	3,484	3,078
Product development and research expenses	6,910	2,743	2,834
Total costs and expenses	29,834	18,306	11,699
Operating income (loss)	3,906	-82	-3,136
Other Income (Expense):
Change in the fair value of derivative liability	2,300	0	0
Interest and other expense, net	-782	-199	-975
Income (loss) before income tax expense (benefit)	5,424	-281	-4,111
Income tax expense (benefit)	173	-197	-184
Net income (loss)	5,251	-84	-3,927
Preferred stock dividend	0	-1,308	0
Net income (loss) attributable to common stockholders	$5,251	($1,392)	($3,927)
Basic income (loss) per share	$0.11	($0.03)	($0.10)
Diluted income (loss) per share	$0.09	($0.03)	($0.10)
Weighted average shares of common stock outstanding:
Basic (in shares)	49,817,721	43,517,640	39,786,446
Diluted (in shares)	64,207,190	43,517,640	39,786,446

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	$5,251	($84)	($3,927)
Reconciliation of net income (loss) to net cash used in operating activities:
Depreciation and amortization of fixed assets	415	375	357
Amortization of license fee	100	100	100
Provision for write down of inventory	228	110	138
Issuance of stock to consultant	80
Stock based compensation expense	823	536	378
Amortization of debt issuance costs	107	31	862
Amortization of product acquisition costs	120	60	0
Amortization of debt discount on convertible 3.75% senior notes	261	0	0
Change in the fair value of derivative liability	-2,300	0	0
Loss on abandonment of property	0	0	9
Changes in operating assets and liabilities:
Accounts receivable	-9,419	-3,370	-369
Inventories	-143	-1,206	-716
Prepaid expenses and other current receivables	-1,075	-402	119
Accounts payable and accrued expenses	2,346	2,528	671
Deferred income	-685	704	5
Net cash used in operating activities	-3,891	-618	-2,373
Cash flows from investing activities:
Capital expenditures	-834	-287	-342
Product acquisition costs	-2,958	-1,826	0
Net cash used in investing activities	-3,792	-2,113	-342
Cash flows from financing activities:
Proceeds from convertible 3.75% senior notes, net of $4,765	138,985	0	0
Proceeds from issuance of stock, net	24,858	0	0
Proceeds from note payable, net of debt issuance costs	2,755	2,000	886
Repayment of note payable	-3,000	0	0
Repayment of note payable, related party	0	0	-500
(Expenses of) proceeds from sale of treasury stock, net of expenses	0	-63	1,963
Proceeds from exercise of common stock options and warrants	837	376	39
Principal payments on capital lease obligations	-64	-17	-51
Excess tax benefits from stock compensation	94	0	0
Net cash provided by financing activities	164,465	2,296	2,337
Net increase (decrease) in cash and cash equivalents	156,782	-435	-378
Cash and cash equivalents at beginning of year	2,101	2,536	2,914
Cash and cash equivalents at end of year	158,883	2,101	2,536
Supplemental Cash flow information:
Cash payments for interest	178	142	99
Cash payments for (receipts from) income taxes	23	-194	-184
Non cash investing and financing transactions:
Bifurcation of derivative from convertible 3.75% senior notes	41,400	0	0
Payable related to product acquisition costs	6,000	0	0
Equipment financed through capital lease	0	20	30
Issuance of restricted stock	0	3	1
Restricted stock forfeiture	0	0	-2
Issuance of warrants	0	0	209
Series C Convertible Preferred Stock And Accrued Dividends Into Common Stock [Member]
Non cash investing and financing transactions:
Conversion of Convertible Preferred Stock	0	2,825	0
Series A Convertible Preferred Stock Into Common Stock [Member]
Non cash investing and financing transactions:
Conversion of Convertible Preferred Stock	$0	$500	$0

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (Convertible Notes Payable [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 16, 2014
Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.75%	3.75%
Payments of Debt Issuance Costs	$4,765

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock Issued For Series A Convertible Preferred Stock [Member]	Common Stock Issued For Series C Convertible Preferred Stock Including Dividend [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
In Thousands, except Share data	Total			Series A Preferred Stock [Member]	Common Stock Issued For Series A Convertible Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Common Stock Issued For Series A Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issued For Series A Convertible Preferred Stock [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Balance at Dec. 31, 2011	$7,765			$500		$1,517	$415		$46,246		($39,518)	($1,395)
Balance (in Shares) at Dec. 31, 2011				50		1,550	41,463,836
Stock based compensation expense	378								378
Restricted stock issuance	0						1		-1
Restricted stock issuance (in Shares)							109,748
Restricted stock forfeiture	-2						-2		2
Restricted stock forfeited (in Shares)							-177,084
Stock options exercised	26								26
Stock options exercised (in Shares)							40,000
Stock warrants exercised	13						13
Stock warrants exercised (in Shares)							1,268,532
Sale of treasury stock, net of expenses of $36	1,963						19		549			1,395
Fair value of warrants issued	209								209
Net Income (loss)	-3,927			0		0	0		0		-3,927	0
Balance at Dec. 31, 2012	6,427			500		1,517	446		47,409		-43,445	0
Balance (in Shares) at Dec. 31, 2012				50		1,550	42,705,032
Stock based compensation expense	536								536
Restricted stock issuance	0						3		-3
Restricted stock issuance (in Shares)							325,000
Restricted stock forfeiture	0
Stock options exercised	139						1		138
Stock options exercised (in Shares)							129,336
Stock warrants exercised	236						5		231
Stock warrants exercised (in Shares)							427,713
Costs related to stock issuance	-63								-63
Common stock issued	0	0	0		-500	-1,517	27	5	2,798	495	-1,308
Common stock issued (in Shares)					-50	-1,550	2,661,494	500,000
Net Income (loss)	-84			0		0	0		0		-84	0
Balance at Dec. 31, 2013	7,191			0		0	487		51,541		-44,837	0
Balance (in Shares) at Dec. 31, 2013				0		0	46,748,575
Stock based compensation expense	823								823
Restricted stock forfeiture	0
Stock options exercised	509						5		504
Stock options exercised (in Shares)							443,166
Stock warrants exercised	328						3		325
Stock warrants exercised (in Shares)							270,546
Issuance of stock pursuant to a public offering, net of associated fees of $1,868	24,858						53		24,805
Issuance of stock pursuant to a public offering, net of associated fees of $1,868 (in Shares)							5,347,500
Issuance of stock to consultant	80								80
Issuance of stock to consultant (in shares)							10,000
Excess tax benefits from stock compensation	94								94
Net Income (loss)	5,251			0		0	0		0		5,251	0
Balance at Dec. 31, 2014	$39,134			$0		$0	$548		$78,172		($39,586)	$0
Balance (in Shares) at Dec. 31, 2014				0		0	52,819,787

CONSOLIDATED_STATEMENT_OF_STOC1

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Payments of Stock Issuance Costs	$1,868		$36
Dividends, Preferred Stock	$0	$1,308	$0

Summary_of_Significant_Account

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

1. Summary of Significant Accounting Policies

Nature of the Business

IGI Laboratories, Inc. is a Delaware corporation formed in 1977. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s mission is to become a leader in the specialty generic pharmaceutical market. Under its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets.

Currently, the Company has two platforms for growth:

•

Developing, manufacturing, and marketing a portfolio of generic pharmaceutical products under our own label in topical, injectable, complex and ophthalmic dosage forms; and,

•

Managing our current contract manufacturing and formulation services business.

In addition, we will continue to explore ways to accelerate our growth through the creation of unique opportunities from the acquisition of additional intellectual property, and the expansion of the use of our existing intellectual property, including our licensed Novasome® technology.

To date, we have filed 24 Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA, for additional pharmaceutical products. We expect to continue to expand our presence in the generic pharmaceutical market through the filing of additional ANDAs with the FDA and the subsequent launch of products as these applications are approved. Our target is to file at least 20 ANDAs in 2015 through our internal research and development program. On March 12, 2014, the Company received its first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. On May 7, 2014, the Company received tentative approval from the FDA for its ANDA for diclofenac sodium 1.5% topical solution. On June 26, 2014, the Company executed an agreement to enable it to launch the product in March 2015 after final FDA approval. We will also seek to license or acquire further products, intellectual property, or ANDAs to expand our portfolio.

On September 24, 2014, we acquired from AstraZeneca Pharmaceuticals LP ANDAs and NDAs associated with eighteen products, seventeen of which were injectable products. On September 30, 2014, we acquired ANDAs and NDAs associated with two ophthalmic products from Valeant Pharmaceuticals North America LLC and Valeant Pharmaceuticals Luxembourg SARL (Valeant), in addition to the exclusive right to acquire three additional injectable products from Valeant. One of these additional products was acquired from Valeant on November 18, 2014.

On February 1, 2013, we acquired assets and intellectual property, including an ANDA, for econazole nitrate cream 1%, which we launched in September 2013.

IGI also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as the OTC and cosmetic markets. These products are used in a wide range of applications from cosmetics and cosmeceuticals to the prescription treatment of conditions like dermatitis, psoriasis, and eczema. IGI is currently exploring various options to enable us to expand our development and manufacturing capabilities to include sterile injectable and ophthalmic products.

Principles of Consolidation

The consolidated financial statements include the accounts of IGI Laboratories, Inc. and its wholly-owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated.

Cash Equivalents

Cash equivalents consist of short-term investments, which have original maturities of 90 days or less. These include direct obligations of the U.S. Treasury, including bills, notes and bonds, as well as obligations issued or guaranteed by agencies or instrumentalities of the U.S. government including government-sponsored enterprises (GSEs).

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, notes payable, accounts payable, capital leases and other accrued liabilities at December 31, 2014 approximate their fair value for all periods presented.

The Company measures fair value in accordance with ASC 820-10, "Fair Value Measurements and Disclosures". ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The Company measures its derivative liability at fair value. The derivative convertible option related to Convertible Notes issued December 16, 2014 was valued using the “with” and “without” analysis. A “with” and “without” analysis is a standard valuation technique for valuing embedded derivatives by first considering the value of the Convertible Notes with the option and then considering the value of the Convertible Notes without the option. The difference is the fair value of the embedded derivatives. The convertible note derivative is classified within Level 3 because it is valued using the “with” and “without” method, which does utilize inputs that are unobservable in the market.

The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2014:

Fair value measurement at reporting date using

Quoted prices in

Significant

active markets for

other

Significant

identical assets

observable

unobservable

Derivative liabilites on account of convertible notes

Balance

(Level 1)

inputs (Level 2)

inputs (Level 3)

As of December 31, 2014

41,400

Based on the closing price of the Company’s common stock as of December 31, 2014, the fair value of the Notes was approximately $141.5 million compared to their face value of $143.75 million as of December 31, 2014. However, this variance is due to the conversion feature in the Notes rather than to changes in market interest rates. The Notes carry a fixed interest rate and therefore do not subject the Company to interest rate risk. As a result in the change in fair value,the Company recorded a $2.3 million change in the fair value of the derivative liability on the consolidated statements of operations.

Accounts Receivable and Allowance for Doubtful Accounts

The Company extends credit to its contract services customers based upon credit evaluations in the normal course of business, primarily with 30-day terms. The Company does not require collateral from its customers. Bad debt provisions are provided for on the allowance method based on historical experience and management’s evaluation of outstanding accounts receivable. The Company reviews the allowance for doubtful accounts regularly, and past due balances are reviewed individually for collectability. The Company charges off uncollectible receivables against the allowance when the likelihood of collection is remote.

The Company extends credit to wholesaler and distributor customers and national retail chain customers, based upon credit evaluations, in the normal course of business, primarily with 60-day terms. The Company maintains customer-related accruals and allowances that consist primarily of chargebacks, rebates, sales returns, shelf stock allowances, administrative fees and other incentive programs. Some of these adjustments relate specifically to the generic prescription pharmaceutical business. Typically, the aggregate gross-to-net adjustments related to these customers can exceed 50% of the gross sales through this distribution channel. Certain of these accruals and allowances are recorded in the balance sheet as current liabilities and others are recorded as a reduction to accounts receivable.

Concentration of Credit Risk

Financial instruments, which subject the Company to concentrations of credit risk, consist primarily of cash equivalents and trade receivables. These include direct obligations of the U.S. Treasury, including bills, notes and bonds, as well as obligations issued or guaranteed by agencies or instrumentalities of the U.S. government including government-sponsored enterprises (GSEs), which are not federally insured.

The Company maintains its cash in accounts with quality financial institutions. Although the Company currently believes that the financial institutions with which the Company does business will be able to fulfill their commitments to us, there is no assurance that those institutions will be able to continue to do so.

In 2014, the Company had sales to two customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $10.5 million and $4.4 million, respectively, and represented 44% of total revenues in the aggregate. Accounts receivable related to the Company’s major customers comprised 42% of all accounts receivable as of December 31, 2014.

In 2013, the Company had sales to three customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million, $2.2 million and $2.1 million, respectively, and represented 39% of total revenues in the aggregate. Accounts receivable related to the Company’s major customers comprised 11% of all accounts receivable as of December 31, 2013.

In 2012, the Company had sales to two customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million and $1.8 million, respectively, and represented 54% of total revenues in the aggregate. Accounts receivable related to the Company’s major customers comprised 59% of all accounts receivable as of December 31, 2012.

The Company had net revenue from one product, econazole nitrate cream, which accounted for 38% of total revenues in 2014. The Company did not have significant revenue from any one product in 2013 or 2012.

Inventories

Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. The company records an inventory reserve for losses associated with dated and expired raw materials. This reserve is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. Management does not believe the Company’s inventory is subject to significant risk of obsolescence in the near term. Reserve for obsolescence included in inventory at December 31, 2014 and 2013 were $0.2 million and $0.2 million respectively.

Property, Plant and Equipment

Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows:

Useful Lives

Buildings and improvements

10 - 30 years

Machinery and equipment

3 - 10 years

Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results.

Intangible Assets

Intangible assets consist of the cost of an acquired product and product rights. Intangible assets are amortized over fifteen years (the asset’s estimated useful life).

Long-Lived Assets

In accordance with the provisions of ASC 360-10-55, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In performing such review for recoverability, the Company compares expected future cash flows of assets to the carrying value of the long-lived assets and related identifiable intangibles. If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying value of the assets and their estimated fair value, with fair values being determined using projected discounted cash flows at the lowest level of cash flows identifiable in relation to the assets being reviewed. As of December 31, 2014, no impairments existed.

Accrued Expenses

Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. For the fiscal year ended December 31, 2014, the largest component of accrued expenses was accrued wholesaler fees of $1.7 million, accrued payroll of $1.4 million, accrued royalties of $0.7 million, accrued consulting fees of $0.3 million, accrued interest expense of $0.2 million and accrued directors’ fees of $0.1 million. For the fiscal year ended December 31, 2013, the largest component of accrued expenses was accrued royalties of $0.9 million, accrued payroll of $0.7 million, accrued wholesaler fees of $0.6 million and accrued directors’ fees of $0.2 million.

License Fee

License fees are amortized on a straight-line basis over the life of the agreement (10 years).

Accounting for Environmental Costs

Accruals for environmental remediation are recorded when it is probable a liability has been incurred and costs are reasonably estimable. The estimated liabilities are recorded at undiscounted amounts. Environmental insurance recoveries are included in the statement of operations in the year in which the issue is resolved through settlement or other appropriate legal process.

Income Taxes

The Company records income taxes in accordance with ASC 740-10, “Accounting for Income Taxes,” under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to operating loss and tax credit carry forwards and differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded based on a determination of the ultimate realizability of future deferred tax assets. A valuation allowance equal to 100% of the net deferred tax assets has been recognized due to uncertainty regarding the future realization of these assets.

The Company complies with the provisions of ASC 740-10-25 that clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements in accordance with ASC 740-10, “Accounting for Income Taxes,” and prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There were no unrecognized tax benefits as of the date of adoption. As such, there are no unrecognized tax benefits included in the balance sheet that would, if recognized, affect the effective tax rate.

Revenue Recognition

The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.

The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers included in product sales, and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.

Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.

IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.

Revenue and Provision for Sales Returns and Allowances

As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. These provisions are adjusted as estimates are based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.

The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.

Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.

Gross-To-Net Sales Deductions

Years Ended December 31,

2014

2013

2012

(in thousands)

Gross IGI product sales

51,136

15,001

Reduction to gross product sales:

Chargebacks and billbacks

-26,940

-6,050

Sales discounts and other allowances

-4,366

-1,593

-1

Total reduction to gross product sales

-31,306

-7,643

-1

Net IGI product sales

19,830

7,358

Accounts receivable are presented net of SRA balances of $5.6 million and $1.9 at December 31, 2014 and 2013, respectively. Accounts payable and accrued expenses include $1.7 million and $0.6 at December 31, 2014 and 2013, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $3.1 million, $0.9 million and $0 for the years ended December 31, 2014, 2013 and 2012, respectively, were included in cost of goods sold.

In addition, in connection with four of the six products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated on the basis of net sales to one of its pharmaceutical partners. The royalty is calculated based on contracted terms of 40% of net sales for the four products which is to be paid quarterly to the pharmaceutical partner. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.7 million and $0.9 at December 31, 2014 and 2013, respectively, related to these royalties. Royalty expense of $3.6 million, $2.6 million and $0 was included in cost of goods sold for the twelve months ended December 31, 2014, 2013, and 2012 respectively. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.

Contract Manufacturing Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products included in product sales, net in the statement of operations.

Research and Development Income: The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.

In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.

Licensing and Royalty Income: Revenues earned under licensing or sublicensing contracts are recognized as earned in accordance with the terms of the agreements. The Company recognizes royalty revenue based on royalty reports received from the licensee. The Company does not have current plans to have meaningful revenue from licensing and royalty agreements in 2015.

Stock-Based Compensation

ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the vesting period of the grant.

Debt Issuance Costs

Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan. See detailed amounts per year in Notes 6, 7 and 8.

Product Development and Research

The Company's research and development costs are expensed as incurred.

Shipping and Handling Costs

Costs related to shipping and handling is comprised of outbound freight and the associated labor. These costs are recorded in costs of sales.

Net Income (Loss) per Common Share

Basic net income (loss) per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the convertible 3.75% senior notes and the exercise of options and warrants and the conversion of preferred stock. Due to the net loss for the years ended December 31, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each year; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. As of December 31, 2013, the shares of common stock issuable in connection with stock options and warrants of 2,998,406, and as of December 31, 2012, the shares of common stock issuable in connection with stock options and warrants and the conversion of preferred stock of 6,445,628 were not included in the diluted income per common share calculation since their effect was anti-dilutive.

For the years ended December 31, 2014, 2013 and 2012

(in thousands except shares and per share data)

2014

2013

2012

Basic earnings per share computation:

Net income (loss) attributable to common stockholders —basic

5,251

-1,392

-3,927

Weighted average common shares —basic

49,817,721

43,517,640

39,786,446

Basic net income (loss) per share

0.11

-0.03

-0.1

Dilutive earnings per share computation:

Net income (loss) attributable to common stockholders —basic

5,251

-1,392

-3,927

Interest expense related to convertible 3.75% senior notes

224

Net income (loss) attributable to common stockholders —diluted

5,475

-1,392

-3,927

Share Computation:

Weighted average common shares —basic

49,817,721

43,517,640

39,786,446

Effect of convertible 3.75% senior notes

12,732,168

Effect of dilutive stock options and warrants

1,657,301

Weighted average common shares outstanding —diluted

64,207,190

43,517,640

39,786,446

Diluted net income (loss) per share

0.09

-0.03

-0.1

Derivatives

The Company accounts for its derivative instruments in accordance with ASC 815-10, “Derivatives and Hedging” (“ASC 815-10”). ASC 815-10 establishes accounting and reporting standards requiring that derivative instruments, including derivative instruments embedded in other contracts, be recorded on the balance sheet as either an asset or liability measured at its fair value. ASC 815-10 also requires that changes in the fair value of derivative instruments be recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. The Company's derivative liability is the embedded convertible option of its Convertible Notes issued December 16, 2014 (as defined in Note 6), all of which have been recorded as a liability at fair value, and are revalued at each reporting date, with changes in the fair value of the instruments included in the consolidated statements of operations as non-operating income (expense).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include valuation of the derivative liability, SRA allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowances, stock based compensation and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In May 2014, FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers”. This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January 1, 2017. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU and management is currently evaluating which transition approach to use. The Company is currently evaluating the impact of ASU 2014-09.

In August 2014, FASB issued Accounting Standards Update (“ASU”) 2014-15, “Presentation of Financial Statements — Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This ASU requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2014-15.

Liquidity

Liquidity	12 Months Ended
Liquidity	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Liquidity

	The Company’s principal sources of liquidity are cash and cash equivalents of approximately $158,883,000 at December 31, 2014, the $6,840,000 available under the $10,000,000 credit facility, (See Note 7).

	On December 10, 2014, the Company entered into a purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell its 3.75% Convertible Senior Notes due 2019 (the “Notes”) The company received net proceeds of approximately $139 million after expenses of approximately $4.8 million upon completion of the transaction. (See Note 6)

	The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity or through a strategic alliance with a third party. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that our existing capital resources will be sufficient to support its current business plan and operations beyond March 2016.

License_Fee

License Fee	12 Months Ended
License Fee	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments Disclosure [Text Block]	3. License Fee

	On December 12, 2005, the Company extended its license agreement for an additional ten years with Novavax, Inc. for $1,000,000. This extension entitles the Company to exclusive use of the Novasome® lipid vesicle encapsulation and certain other technologies in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals, and the processes for making the same through 2015. This payment is being amortized ratably over the ten-year period. For the years ended, December 31, 2014, 2013 and 2012, the Company recorded a $100,000 expense in each year related to the amortization of the license. Remaining amortization of this license fee will amount to $100,000 in 2015.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4. Inventories

	Inventories as of December 31, 2014 and 2013 consisted of:

		2014		2013
		(in thousands)

	Raw materials	$	2,299	$	2,172
	Work in progress		140		271
	Finished goods		345		426
		$	2,784	$	2,869

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment

	Property, plant and equipment, at cost, as of December 31, 2014 and 2013, consisted of:

		2014		2013
		(in thousands)

	Land	$	257	$	257
	Building and improvements		3,775		3,599
	Machinery and equipment		4,156		3,375
	Construction in progress		225		128
			8,413		7,359
	Less accumulated depreciation and amortization		-5,151		-4,736

	Property, plant and equipment, net	$	3,262	$	2,623

	The Company recorded depreciation and amortization expense of $415,000, $375,000 and $357,000 in 2014, 2013 and 2012, respectively.

Convertible_375_Senior_Notes

Convertible 3.75% Senior Notes	12 Months Ended
Convertible 3.75% Senior Notes	Dec. 31, 2014
Debt Disclosure [Abstract]
Convertible debt disclosure [Text Block]	6. Convertible 3.75% Senior Notes

	On December 16, 2014, the Company issued $125 million aggregate principal amount of 3.75% Convertible Senior Notes due 2019, or the Notes. On December 22, 2014, the Company announced the closing of the initial purchasers’ exercise in full of their option to purchase an additional $18.75 million aggregate principal amount. The Notes were offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The net proceeds from the sale of the Notes were approximately $139 million, after deducting underwriting fees and other related expenses of approximately $4.8 million. Accrued interest in the amount of $0.2 million related to the Notes was included in accrued expenses.

	The Notes bear interest at a fixed rate of 3.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2015 and mature on December 15, 2019, unless earlier repurchased, redeemed or converted. The Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. However, if the Company has not received stockholder approvals to increase the number of authorized shares of the Company’s common stock and comply with certain listing standards of the NYSE MKT, the Company would be required to satisfy any conversion obligations solely in cash or, at the Company’s option subject to certain conditions and limitations, in shares of the Company’s common stock. The Notes are convertible at an initial conversion price of approximately $11.29 per share, which is equivalent to an initial conversion rate of 88.5716 shares per $1,000 principal amount of Notes, subject to adjustment in certain events, such as distributions of dividends or stock splits. Holders may convert their Notes at their option prior to September 15, 2019, when or if certain conditions have been met or circumstances have occurred, such as the Company’s stock price exceeds 130% of the conversion price under the Notes for a designated period of time, or the trading price of the Notes is, for a designated period of time, less than 98% of the closing sale price of the Company’s common stock multiplied by the then-current conversion rate of the Notes, or the Company calls Notes for redemption, or certain specified corporate events occur. Holders may also convert their Notes at their option at any time on or after September 15, 2019 and prior to the close of business on the business day immediately preceding the stated maturity date. In addition, following the occurrence of certain changes of control of the Company described in the Indenture governing the Notes or termination of trading of the Company’s common stock or other securities into which the Notes are convertible (a “make-whole fundamental change”) or the delivery by the Company of a notice of redemption, the conversion rate for a holder who elects to convert its Notes in connection with such make-whole fundamental change or such notice of redemption will increase in certain circumstances. Additionally, subject to certain conditions, the Company may redeem for cash any or all outstanding Notes on or after December 19, 2017 in an amount equal to the outstanding principal amount of such Notes, plus accrued and unpaid interest.

	The Notes and any common stock issuable upon conversion of the Notes have not been registered under the Securities Act, applicable state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The Company does not intend to file a registration statement for the resale of the Notes or any common stock issuable upon conversion of the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

	Since the Company does not have sufficient authorized shares available to share-settle the conversion option in full, the embedded conversion option does not qualify for equity classification and instead is separately valued and accounted for as a derivative liability. On December 16, 2014, the initial value allocated to the derivative liability was $43.7 million of the $143.75 million principal amount of the Notes, which represents a discount to the debt to be amortized through interest expense using the effective interest method through the maturity of the Notes. Accordingly, the effective interest rate used to amortize the debt discount on the Notes is 12.94%. During each reporting period, the derivative liability is marked to fair value through the statement of operations. As of December 31, 2014, the derivative liability, which is classified in long-term liability, had a fair value of $41.4 million. This resulted in a change in the fair value of the derivative liability of $2.3 million for the year ended December 31, 2014. If the Company receives shareholder approval for the increase in the number of shares of common stock authorized and available for issuance upon conversion of the Notes so the conversion option can be share-settled in full, the conversion option may qualify for equity classification and the bifurcated derivative liability would no longer need to be accounted for as a separate derivative on a prospective basis from the date of reassessment. Any remaining debt discount that arose at the date of debt issuance from the original bifurcation will continue to be amortized through interest expense.

	The Notes are being accounted for in accordance with ASC 470-20. Under ASC 470-20, issuers of convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, are required to separately account for the liability (debt) and equity (conversion option) components.

	The application of ASC 470-20 resulted in the recognition of $43.7 million as the value for the liability at December 31, 2014. The remaining unamortized discount and unamortized debt financing costs will be amortized over the remaining term of 4.95 years. At December 31, 2014 the net carrying amount of the liability component and the remaining unamortized debt discount were as follows:

			December 31,
			2014
			(in thousands)

	Face Amount of the Notes		$	143,750
	Unamortized discount of the liability component			43,439
	Carrying amount of the Notes		$	100,311

	Deferred financing costs associated with the Notes, include fees of $4.7 million at December 31, 2014. The assumptions used in connection with the valuation of the convertible option of the Notes issued December 16, 2014 utilizing the "with” and “without” method, discussed in Note 2 was as follows:

			Initial Measurement				Measurement
			December 16,				December 31,
			2014				2014
	Issue date			12/17/14				12/17/14
	Maturity date			12/15/19				12/15/19
	Term			4.99				4.92
	Principal (millions)			143.75				143.75
	Coupon			3.75	%			3.75	%
	Seniority			Senior unsecured				Senior unsecured
	Conversion shares			88.572				88.572
	Conversion price		$	11.29			$	11.29

	Stock price		$	9.45			$	8.8
	Risk free rate			1.61	%			1.64	%

	Volatily (rounded)			40	%			40	%

	The table below provides a reconciliation of beginning and ending balances for the liability measured at fair value using significant observable and unobservable inputs (Level 3). The table reflects the gain for the year ended December 31, 2014 associated with the decrease in fair value.

			Initial
			Measurement
			December 16,			Decrease in			December 31,
			2014			Fair Value			2014
	Fair Value of Convertible Feature of Convertible 3.75% Senior Notes		$	43,700		$	2,300		$	41,400

	For the year ended December 31, 2014, the Company recorded the following expenses in relation to the Notes:

			December 31,
			2014
			(in thousands)

	Interest Expense at 3.75% coupon rate		$	225
	Debt Discount Amortization			261
	Amortization of deferred financing costs			28
	Total interest expense (1)		$	514

		-1	Included within “Interest and other expense, net” on the Consolidated Statements of Operations

Note_Payable_General_Electric_

Note Payable - General Electric Capital Corporation (General Electric Capital Corporation [Member])	12 Months Ended
	Dec. 31, 2014
General Electric Capital Corporation [Member]
Note Payable [Line Items]
Debt Disclosure [Text Block]	7. Note Payable – General Electric Capital Corporation

	On November 18, 2014, the Company entered into an asset-based revolving senior secured credit facility (the “Credit Agreement”) with General Electric Capital Corporation, as agent (the “Agent”), and GE Capital Bank and the other financial institutions party thereto, as lenders (the “Lenders”), pursuant to which the Lenders agreed to extend credit facilities to the Company (the “Financing”).

	To secure payment of the amounts financed under the Credit Agreement, the Company and the Agent entered into a Guaranty and Security Agreement (the “Guaranty and Security Agreement”). Under the terms of the Guaranty and Security Agreement, the Company granted to the Agent, for the benefit of the Lenders and other secured parties, a continuing security interest in and against substantially all of its tangible and intangible assets, except intellectual property, and each of the Company’s direct and indirect future subsidiaries shall guarantee the Company’s’ obligations under the Credit Agreement.

	Under the Credit Agreement, the Company can request revolving loan advances up to an aggregate total amount of $10,000,000, which may be increased to $15,000,000 at the request of the Company if certain conditions are met. The Company may also request an incremental facility for revolving loan commitments of up to $10,000,000. Borrowings under the Credit Agreement may be made as prime rate loans with an applicable margin of 3.0% per annum or 1, 2, 3 or 6 month LIBOR loans with an applicable margin of 4.0% per annum. At December 31, 2014, the interest rate in effect was 4.2%. Availability under the Credit Agreement is calculated as 85% of the book value of eligible accounts at such time multiplied by a liquidity factor, less any reserves established by the Agent. As of December 31, 2014, the outstanding balance of the credit facility was $3,160,000. In accordance with the Credit Agreement, the Company is required to provide the Lenders information related to working capital by which the Lenders will calculate the available line of credit, defined in the agreement as the Borrowing Base Certificate. As of December 31, 2014, the Company had a remaining availability of $6,744,000.

	The term of the Credit Agreement is up to five years from November 18, 2014. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, covenants that limit or restrict the Company’s ability to incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make distributions, or repurchase stock, in each case, subject to customary exceptions for a loan facility of this size and type. In addition, the Credit Agreement contains customary events of default (subject to customary cure periods for certain events of default), including, among others, non-payment, inaccuracy of representations and warranties, covenant defaults, cross-default to material agreements, cross-default to material indebtedness, bankruptcy and insolvency and material judgment defaults. The Company must meet certain financial reporting and audit requirements, as defined by the credit agreement. The Company was in compliance with all other covenants of the Credit Agreement as of December 31, 2014.

	In connection with the Financing, the Company paid in full its existing credit facility with Square 1 Bank (Note 8) and executed a Release and Termination Note and Credit Agreement with Square 1 Bank to release the Company from any future obligations under the Credit Agreement executed on August 31, 2012, as amended July 26, 2013.

Note_Payable_Square_1_Bank

Note Payable - Square 1 Bank (Square 1 Bank Loan [Member])	12 Months Ended
Note Payable - Square 1 Bank (Square 1 Bank Loan [Member])	Dec. 31, 2014
Square 1 Bank Loan [Member]
Note Payable [Line Items]
Debt Disclosure [Text Block]	8. Note Payable – Square 1 Bank

	On August 31, 2012, as amended on July 26, 2013, the Company entered into a Loan and Security Agreement (the Loan and Security Agreement) with Square 1 Bank (the Lender) pursuant to which the Lender agreed to extend credit facilities to the Company. The Company drew down $1,000,000 in principal on August 31, 2012, $1,000,000 in principal on February 5, 2013 and $1,000,000 in principal on August 2, 2013.

	On November 18, 2014, the Company paid in full its existing credit facility with the Lender under the Loan and Security Agreement. The Company recorded amortization expense in the amount of $42,000 to write-off the remaining unamortized debt issuance costs.

	To secure payment of the amounts financed under the Loan and Security Agreement, the Company granted to the Lender a continuing security interest in and against, generally, all of its tangible and intangible assets, except intellectual property.

	In connection with the financing, the Company paid in full its existing credit facility with Amzak Capital Management, LLC (see Note 9 below) and executed a Release and Termination Note and Credit Agreement with Amzak Capital Management, LLC to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010 (the Amzak Credit Facility).

Note_Payable_Former_Related_Pa

Note Payable - Former Related Party	12 Months Ended
Note Payable - Former Related Party	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Note Payable – Former Related Party

	On December 21, 2010, the Company entered into a Credit Agreement with Amzak Capital Management, LLC, (“Amzak”) pursuant to which Amzak extended a $3,000,000 credit facility to the Company (the Credit Agreement).

	On August 31, 2012, the Company paid in full its existing credit facility with Amzak and executed a Release and Termination Note and Credit Agreement to release the Company from any future obligations under the Credit Agreement. In addition, the Company received the discharge of mortgage notification indicating the mortgage related to this credit agreement was satisfied and discharged. In connection with the release and termination agreement, the Company recorded amortization expense in the amount of $545,000 to write-off the remaining unamortized debt issuance costs.

	The interest rate applicable to each promissory note was 14% per annum and interest payments were due on each March 31, June 30, September 30 and December 31 during the term of the Credit Agreement.

	In addition, as consideration for entering into the Credit Agreement, on December 21, 2010, the Company issued to the Lender a ten-year warrant to purchase certain shares of the Company’s common stock, at an exercise price of $0.01 per share (the “Warrant”). The Warrant was immediately exercisable for 881,331 shares of Common Stock (the “Initial Warrant Shares”) with the remaining shares of Common Stock representing 1% of the Fully Diluted Shares (as defined therein) as of the Conditional Warrant Exercise Date (as defined therein) (the “Conditional Warrant”) became exercisable on July 1, 2012 if the Company had not achieved certain milestones related to the Company’s product development or financial growth. The Warrant was accounted for as an equity instrument. The fair value of the Initial Warrant of $724,000 was recorded as debt issuance costs and amortized on a straight-line basis, which approximated the effective interest method, over the stated term of the Credit Agreement of five years. Amortization expense of $639,000 was recognized for the year ended December 31, 2012. In August of 2012, upon termination of the credit agreement, the unamortized portion of the initial warrant of $545,000 was recognized as interest expense.

	The Initial Warrant for 881,331 shares was exercised on September 28, 2012. On December 21, 2010, the fair value of the Conditional Warrant was not considered to be material. As of December 31, 2012, the Company executed a settlement agreement with Amzak Capital Management, LLC in connection with the Conditional Warrant and issued to Amzak on December 21, 2010 a ten-year warrant to purchase up to 427,713 shares of its common stock, with an exercise price of $0.55 per share. The warrants were exercised in full on February 8, 2013. The Company recorded the fair value of the Conditional Warrant of $209,000 as debt issuance costs which was included in interest expense in 2012.

	The Lender is a shareholder of the Company and participated in the private placement on December 8, 2010.

Series_A_Convertible_Preferred

Series A Convertible Preferred Stock (Series A Preferred Stock [Member])	12 Months Ended
	Dec. 31, 2014
Series A Preferred Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock [Text Block]	10. Series A Convertible Preferred Stock

	On December 5, 2007, pursuant to a subscription agreement entered into with an accredited investor, the Company sold (i) 50 shares of Series A Convertible Preferred Stock with a liquidation preference of $10,000 per share, with each share of preferred stock, convertible into 10,000 shares of common stock of the Company, subject to customary adjustments; and (ii) a warrant to purchase 175,000 shares of common stock at an exercise price of $1.25 per share that expired on December 5, 2009, two years from issuance, for aggregate consideration of $500,000.

	The Series A Convertible Preferred Stock was convertible, at the option of the holders, into shares of the Company’s common stock at a conversion price of $1.00 per share. Based on the original purchase price of $10,000 per share of preferred, each share of Series A Convertible Preferred Stock was convertible into 10,000 shares of common stock. The Series A Convertible Preferred Stock also contained an automatic conversion wherein the shares would automatically convert into shares of common stock when the closing price of the Company’s common stock is $2.50 for ten consecutive trading days.

	The Company has a total of 1,000,000 of authorized shares of preferred stock, par value $0.01, of which 100 shares were designated as Series A Convertible Preferred Stock.

	On September 5, 2013, at the option of the holder, all of the issued and outstanding shares of the Series A Convertible Preferred Stock were converted into 500,000 shares of the Company’s common stock, at a conversion price of $1.00 per share.

Series_C_Convertible_Preferred

Series C Convertible Preferred Stock - 2010 Offering (Series C Convertible Preferred Stock [Member])	12 Months Ended
	Dec. 31, 2014
Series C Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Line Items]
Preferred Stock [Text Block]	11. Series C Convertible Preferred Stock – 2010 Offering

	On March 29, 2010, the Company completed a $1,550,000 private placement with certain investors, including investment funds affiliated with Signet Healthcare Partners, G.P. and Jane E. Hager (the “Series C Offering”). As part of the Series C Offering, the Company issued 1,550 shares of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock has a par value of $0.01 per share and the holders were entitled to quarterly dividends at an annual rate of 5%, when and if declared by the Board of Directors. Furthermore, each share of Series C Convertible Preferred Stock was convertible into shares of common stock equal to (i) 1,000 plus any accrued and unpaid dividends, divided by (ii) $0.69 (the closing price of the Company’s common stock on the date of issuance of the Series C Convertible Preferred Stock).

	The Company has a total of 1,000,000 shares of authorized shares of preferred stock, of which 1,550 shares were designated as Series C Convertible Preferred Stock.

	Pursuant to the terms of the Certificate of Designation, the shares of Series C Preferred Stock automatically converted into shares of the Company’s Common Stock upon the date that the closing price of the Company’s Common Stock exceeded three times the closing price on the issuance date for a period of 25 consecutive trading days immediately preceding such date. Accordingly, on December 6, 2013, all of the shares of Series C Convertible Preferred Stock automatically converted into shares of the Company’s Common Stock.

	On December 6, 2013, the Company recognized a deemed dividend as a component of net loss attributable to common stockholders for the fair value of the additional shares issued to the former preferred stockholders. All of the issued and outstanding shares of the Series C Convertible Preferred Stock, of the Company, as well as accrued dividends of $1,308,000 automatically converted into an aggregate of 2,661,494 shares of the Company’s common stock, par value $0.01 per share, in accordance with the terms and conditions set forth in the original Certificate of Designation of the Rights and Preferences of Series C Convertible Preferred Stock, which specified a $0.69 conversion ratio.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12. Stock-Based Compensation

	The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 shares have been approved and authorized for issuance pursuant to this plan. A total of 2,369,798 options have been granted to non-employee directors through December 31, 2014 and 807,782 of those have been forfeited through December 31, 2014 and returned to the option pool. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years.

	The 1999 Stock Incentive Plan, as amended (“1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those previous plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, have been granted at 100% of the fair market value of the Company's common stock at the date of grant. Options outstanding under the 1999 Plan are generally exercisable in cumulative increments over four years commencing one year from date of grant.

	On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2009 Plan, as amended on May 19, 2010, authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of December 31, 2014, options to purchase 2,004,334 shares of common stock were outstanding under the 2009 Plan. As of December 31, 2014, 1,473,748 shares of restricted stock had been granted under the 2009 Plan and 230,420 of those have been forfeited through December 31, 2014 and returned to the pool.

	In summary, there are 2,436,334 options outstanding under the 1999 Plan, the Director Plan and the 2009 Plan, collectively as of December 31, 2014.

	There are 2,086,820 options available for issuance under the Director Plan, and the 2009 Plan collectively as of December 31, 2014.

	Stock Options

	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant.

	Assumptions		2014			2013			2012

	Dividend yield			0	%		0	%		0	%
	Risk free interest rate			0.74% - 1.2	%		0.48	%		0.39	%
	Estimated volatility factor			44.0% - 53.0	%		36.9% – 43.1	%		54.5	%
	Expected life			3.2 – 3.3 years			3.2 – 3.3 years			3.2 years

	Estimated volatility was calculated using the historical volatility of the Company’s stock over the expected life of the options. The expected life of the options was estimated based on the Company’s historical data. The forfeiture rates are estimated based on historical employment/directorship termination experience. The risk free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuation.

	Stock option transactions in each of the past three years under the aforementioned plans in total were:

						Exercise			Weighted Average
			Shares			Price Per Share			Exercise Price
	January 1, 2012 shares issuable under options			1,448,016		$	.55 - 1.74		$	1.16
	Granted			1,551,000			1.02 - 1.18			1.05
	Exercised			-40,000			0.65			0.65
	Expired			-15,000			0.65			0.65
	Forfeited			-337,516			.55 - 1.52			1.22
	December 31, 2012 shares issuable under options			2,606,500			.55 - 1.74			1.1
	Granted			247,000			1.04 - 3.03			1.35
	Exercised			-129,336			1.02 - 1.27			1.08
	Expired			—			—			—
	Forfeited			-80,664			1.10 - 1.74			1.3
	December 31, 2013 shares issuable under options			2,643,500			.55 - 3.03			1.12
	Granted			397,500			2.96 – 10.55			5.89
	Exercised			-443,166			.55 – 1.95			1.15
	Expired			—
	Forfeited			-161,000			1.00 – 5.65			2.71
	December 31, 2014 shares issuable under options			2,436,834			0.76 – 10.55			1.79

	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2014:

			Options Outstanding									Options Exercisable
						Weighted			Weighted						Weighted
						Average			Average						Average
	Range of		Number of			Remaining			Exercise			Number of			Exercise
	Exercise Price		Options			Life (Years )			Price			Options			Price

	$ 0.76 to $ 1.00			97,000			3.04		$	0.78			97,000		$	0.78
	1.01 to 1.50			1,887,500			7.14			1.07			1,448,664			1.08
	1.51 to 10.55			452,334			8.68			5.02			110,333			1.78

	$0.76 to $10.55			2,436,834			7.26		$	1.79			1,655,997		$	1.11

	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2013:

			Options Outstanding									Options Exercisable
						Weighted			Weighted						Weighted
					Average			Average						Average
Range of		Number of			Remaining			Exercise			Number of			Exercise
Exercise Price		Options			Life (Years )			Price			Options			Price

$.55 to $1.00			218,000			4.83		$	0.76			214,000		$	0.75
1.01 to 2.00			2,418,000			7.9			1.14			1,238,496			1.19
2.01 to 3.03			7,500			9.87			2.83			—			—

$.55 to $3.03			2,643,500			7.65		$	1.12			1,452,496		$	1.13


The following table summarizes information concerning outstanding and exercisable options as of December 31, 2012:

		Options Outstanding									Options Exercisable
					Weighted			Weighted						Weighted
					Average			Average						Average
Range of		Number of			Remaining			Exercise			Number of			Exercise
Exercise Price		Options			Life (Years )			Price			Options			Price

$.55 to $1.00			218,000			5.83		$	0.76			212,000		$	0.75
1.01 to 1.50			2,213,500			8.43			1.09			564,001			1.21
1.51 to 1.74			175,000			8.01			1.68			175,000			1.68

$.55 to $1.74			2,606,500			8.19		$	1.1			951,001		$	1.19

The Company has recorded an aggregate of $316,200, $206,500 and $156,000 related to its stock option based expenses in cost of sales, product development and research expenses, and selling, general and administrative expenses on the accompanying Consolidated Statements of Operations for the years ended December 31, 2014, 2013 and 2012, respectively.

The aggregate intrinsic value of options outstanding was $17,103,045 at December 31, 2014, $5,109,925 at December 31, 2013 and $82,270 at December 31, 2012. The aggregate intrinsic value of the options exercisable was $12,738,143 at December 31, 2014, $2,789,901 at December 31, 2013 and $62,410 at December 31, 2012. The total intrinsic value of the options exercised during 2014, 2013 and 2012 was $3,391,030, $254,779 and $15,600, respectively.

A summary of non-vested options at December 31, 2014 and changes during the year ended December 31, 2014 is presented below:

					Weighted Average
		Options			Grant Date Fair Value

Non-vested options at January 1, 2014			1,191,004		$	0.33
Granted			397,500			2.09
Vested			-665,333			0.32
Forfeited			-142,334			0.87
Non-vested options at December 31, 2014			780,837		$	1.12

As of December 31, 2014, there was $657,500 of total unrecognized compensation cost related to non-vested share-based compensation arrangements under the Plan. The costs will be recognized through December 2017.

Restricted Stock

The Company periodically grants restricted stock awards to certain officers and other employees that typically vest one to three years from their grant date. On December 30, 2013, in accordance with the terms of the employment agreement between Jason Grenfell-Gardner, President and CEO, and the Company executed on July 30, 2012, a restricted stock award in the amount of 325,000 shares was granted to Jason Grenfell-Gardner, with one third of the shares of restricted stock vested on December 30, 2013, and the remaining two thirds of the shares of restricted stock vesting in equal amounts on July 30, 2014 and July 30, 2015. The Company recognized $507,100, $329,400 and $222,000, respectively, of compensation expense during the years ended December 31, 2014, 2013 and 2012 related to restricted stock awards. Stock compensation expense is recognized over the vesting period of the restricted stock. At December 31, 2014, the Company had approximately $114,200 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized through July 2015.

		Number of			Weighted Average
		Restricted Stock			Issuance Price

Non-vested balance at January 1, 2012			626,000		$	0.71

Changes during the period:
Shares granted			109,748			1
Shares vested			-529,330			0.76
Shares forfeited			-177,084			0.7
Non-vested balance at January 1, 2013			29,334		$	1

Changes during the period:
Shares granted			325,000			2.86
Shares vested			-108,333			2.86
Shares forfeited			—
Non-vested balance at December 31, 2013			246,001		$	2.64

Changes during the period:
Shares granted			-
Shares vested			-137,667			2.46
Shares forfeited			-
Non-vested balance at December 31, 2014			108,334		$	2.86

Stock_Warrants

Stock Warrants	12 Months Ended
Stock Warrants	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	13. Stock Warrants

	Stock Warrants as of December 31, 2014, 2013 and 201 consisted of:

		2014				2013				2012
				Weighted				Weighted				Weighted
				Average				Average				Average
		Warrants		Exercise Price		Warrants		Exercise Price		Warrants		Exercise Price

	Beginning balance		354,546	$	1.21		782,259	$	0.85		1,235,877	$	0.35

	Stock warrants granted		—		—		—		—		814,914		0.29
	Stock warrants expired		—		—		—		—		—		—
	Stock warrants exercised		-270,546		1.21		-427,713		0.55		-1,268,532		0.01

	Ending balance		84,000	$	1.21		354,546	$	1.21		782,259	$	0.85

	In connection with the private placement of the Company’s Common Stock on December 8, 2010, the Company granted common stock warrants to purchase 338,182 and 16,364 shares, respectively, to each of its two placement agents for $1.21 per share which expire on December 8, 2015. In 2014, 270,546 of these warrants were exercised, and 84,000 remain unexercised.

	In connection with the Credit Agreement with Amzak Capital Management, LLC as more fully described in Note 9, on December 10, 2010, the Company issued a ten-year warrant to purchase 881,331 shares of the Company’s Common Stock for $0.01 per share. The warrant was exercised in full on September 28, 2012.

	In connection with the private placement of the Company’s common stock in 2012, the Company granted common stock warrants to purchase 387,201 shares for $0.01 per share, which expire December 2022. The warrants were exercised in full on December 27, 2012.

	The Company executed as of December 31, 2012 a settlement agreement with Amzak Capital Management, LLC (“Amzak”) in connection with a common stock purchase warrant issued to Amzak on December 21, 2012 under which the Company issued a ten-year warrant to purchase up to 427,713 shares of the Company’s common stock, with an exercise price of $0.55 per share. The warrant was exercised in full on February 8, 2013. The amount of the fair value of the warrant issued was $209,000, and included as interest expense in 2012, as it related to the credit agreement which was terminated in August of 2012.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes

	The Company’s current tax expense (benefit) was $173,000, $(197,000) and $(184,000) for the years ended December 31, 2014, 2013 and 2012, respectively. The provision for (benefit from) income taxes attributable to continuing operations before income taxes for the years ended December 31, 2014, 2013 and 2012 is as follows:

			2014		2013		2012
			(in thousands)
	Current tax expense (benefit):
	Federal		$	97	$	-	$	-
	State and local			76		-197		-184
	Total current tax expense (benefit)			173		-197		-184
	Deferred tax expense (benefit):
	Federal			-		-		-
	State and local			-		-		-
	Total deferred tax expense (benefit)			-		-		-
	Total income tax expense (benefit)		$	173	$	-197	$	-184

	The Company sold the remainder of its New Jersey operating loss carry forwards under a program of the New Jersey Economic Development Authority (NJEDA) in exchange for net proceeds of $197,000 in 2013 and $184,000 in 2012. In order to have realized this benefit, the Company applied to the NJEDA and met various requirements for eligibility.

	The provision for (benefit from) income taxes differed from the amount of income taxes determined by applying the applicable federal tax rate (34%) to pretax income (loss) from continuing operations as a result of the following:

			2014		2013		2012
			(in thousands)
	Expected Statutory expense (benefit)		$	1,844	$	-95	$	-1,381

	Gain on derivative and amortization of debt discount			-693		-		-
	Other non-deductible expenses			3		2		1
	Change in valuation allowance			-1,031		30		1317
	Sale of New Jersey net operating losses			-		-197		-189
	State income taxes, net of federal benefit			50		-
	Federal tax impact of state tax benefit, net			-		63		68
			$	173	$	-197	$	-184

	Deferred tax assets included in the Consolidated Balance Sheets as of December 31, 2014 and 2013 consisted of the following:

			2014		2013
			(in thousands)
	Current Assets:
	Reserves and allowances		$	40	$	121

	Other			647		161
	Total current assets			687		282
	Long Term Assets (Liabilities):
	Property, plant and equipment basis difference			245		209
	Net operating loss carry forwards			9,068		10,672
	Tax credit carry forwards			293		217
	Non-employee stock options			682		685
	Other			-5		-3
	Total Long Term Assets,net			10,283		11,780
	Gross Deferred Tax Asset, net			10,970		12,062
	Less Valuation Allowance			-10,970		-12,062
	Deferred taxes, net		$	-	$	-

	The Company evaluates the recoverability of its net deferred tax assets based on its history of operating results, its expectations for the future, and the expiration dates of the net operating loss carry forwards. Based on the preponderance of the evidence, the Company has concluded that it is more likely than not that it will be unable to realize the net deferred tax assets in the immediate future and has established a valuation allowance for all such net deferred tax assets. Accordingly, the Company has provided a valuation allowance of $11.0 million and $12.1 million for the years ended December 31, 2014 and 2013, respectively, on its net deferred tax assets. The valuation allowance decreased during the year 2014 by $1.1 million related to pre-tax income for the year ended December 31, 2014.

	Operating loss and tax credit carry forwards as of December 31, 2014 were as follows:

			2014		2013
			(in thousands)
	Federal:
	Net operating losses		$	26,602	$	31,308
	Research tax credits (expiring through 2025)			168		168
	Alternative minimum tax credits (available without expiration)			123		28
	State:
	Net operating losses - Tennessee (expiring in 2027)			322		425
Alternative minimum tax assessment - New Jersey (available without expiration)			1		21

At December 31, 2014, the Company’s U.S. federal net operating loss carryforwards will expire as follows:

Year		Net Operating Loss
		(in thousands)

2020		$	5,225
2021			1,157
2022			-
2023			1,232
2024			974
2025			1,850
2026			1,070
2027			308
2028			1,414
2029			3,447
2030			3,455
2031			2,749
2032			3,721

Total		$	26,602

The above excludes net operating losses of $2.4 million which, if realized would be accounted for as additional paid-in capital.

The Company’s ability to use net operating loss carry forwards is subject to substantial limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2010, as well as the limitation on the application of net operating loss carry forwards. The Company believes that operating losses subsequent to the change date in 2010 (aggregating $8.5 million) are not subject to Section 382 limitations. The Company has estimated that the annual limitation starting in 2010 aggregates from $1.0 million to $2.3 million per year including the effect of amortization of built in gains.

The Company is subject to the provisions of ASC 740-10-25, Income Taxes (ASC 740). ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. For federal purposes, post 1998 tax years remain open to examination as a result of net operating loss carryforwards. The Company is currently open to audit by the appropriate state income taxing authorities for tax years 2010 to 2013.

Lease_Commitments

Lease Commitments	12 Months Ended
Lease Commitments	Dec. 31, 2014
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	15. Lease Commitments

	The Company’s commitments and contingencies consisted of operating leases for warehouse and office space and equipment. Future minimum lease payments under non-cancelable operating leases are as follows:

		Amount
	Years Ending December 31,
	2015	$	278,000
	2016		418,000
	2017		410,000
	2018		348,000
	2019		318,000
	Thereafter		1,168,000
	Total	$	2,940,000

	Rent expense was $216,200, $121,700 and $66,900 for the years ended December 31, 2014, 2013 and 2012, respectively.

Legal_and_US_Regulatory_Procee

Legal and U.S. Regulatory Proceedings	12 Months Ended
Legal and U.S. Regulatory Proceedings	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Legal Matters and Contingencies [Text Block]	16. Legal and U.S. Regulatory Proceedings

	On March 2, 2001, the Company became aware of environmental contamination resulting from an unknown heating oil leak at its former manufacturing facility. The Company immediately notified the New Jersey Department of Environmental Protection (NJ DEP) and the local authorities, and hired a contractor to assess the exposure and required clean up. The total estimated costs for the clean-up and remediation is $836,000, of which approximately $80,000 remains accrued as of December 31, 2014. Based on information provided to the Company from its environmental consultant and what is known to date, the Company believes the reserve is sufficient for the remaining remediation of the environmental contamination. There is a possibility, however, that the remediation costs may exceed the Company’s estimates.

	The restricted cash, included in other assets on the Consolidated Balance Sheet of $54,000 as of December 31, 2014 and 2013 represents a restricted escrow account set up on the requirement of the NJ DEP for the soil remediation work. These funds will be released to the Company upon the DEP approval when the remediation is completed.

	On December 19, 2013, we filed a complaint in the United States District Court for the District of Delaware against Mallinckrodt LLC, Mallinckrodt, Inc. and Nuvo Research Inc. (collectively, “Mallinckrodt”) seeking a declaration of non-infringement of United States Patent Nos. 8,217,078 and 8,546,450 so that we can bring our generic diclofenac sodium topical solution 1.5% to market at the earliest possible date under applicable statutory and FDA regulatory provisions.

	On January 10, 2014, Mallinckrodt filed an answer and counterclaim alleging that the Company infringes the patents at issue. On January 28, 2014, we filed a motion to dismiss Mallinckrodt’s counterclaim and, on March 5, 2014, Mallinckrodt filed an opposition to such motion. The court has not yet rendered a decision. The Company believes the complaint has merit, and the Company intends to continue to pursue Mallinckrodt. Based on the early stage of this complaint and counterclaim the Company is unable to predict the outcome.

	On June 26, 2014, the Company entered into an agreement with Mallinckrodt to settle a declaratory judgment action brought by IGI, concerning the Company’s filing of an ANDA with the FDA seeking approval to market a generic version of Pennsaid® (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted the Company a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. There was no material impact on the financial statements as a result of the settlement. The Company received tentative approval to sell its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.

Employee_Benefits

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	17. Employee Benefits

	The Company has a 401(k) contribution plan, pursuant to which employees may elect to contribute to the plan, in whole percentages, up to 100% of compensation. Employees’ contributions are subject to a minimum contribution by participants of 1% of compensation and a maximum contribution of $17,500 for 2014, $17,500 for 2013 and $17,000 for 2012, plus a catch-up contribution of up to $5,500 for 2014, 2013 and 2012, if a participant qualifies. The Company matches 100% of the first 3% of compensation contributed by participants and 50% of the next 2% of compensation contributed by participants. The Company contribution is in the form of cash, which is vested immediately. The Company has recorded charges to expense related to this plan of approximately $126,600, $93,000 and $71,000 in 2014, 2013 and 2012, respectively.

2014_Public_Offering

2014 Public Offering	12 Months Ended
2014 Public Offering	Dec. 31, 2014
Equity [Abstract]
Public Offering Disclosure [Text Block]	18. 2014 Public Offering

	On June 27, 2014, the Company entered into an underwriting agreement with Roth Capital Partners, LLC and Oppenheimer & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to the underwritten public offering and sale of up to an aggregate of 4,650,000 shares of the Company’s common stock, par value $0.01 (the “shares”), at a price to the public of $5.00 per share (the “Offering”). The Company also granted the underwriters a 30-day option to purchase up to an aggregate of 697,500 shares to cover over-allotments, if any.

	The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-196543), filed on June 5, 2014 with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on June 16, 2014, as well as the prospectus supplement describing the terms of the Offering, dated June 27, 2014.

	On July 2, 2014, the Company closed the Offering, and after giving effect to the underwriters’ exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the Offering at a public offering price of $5.00 per share. The net proceeds of the Offering were approximately $24.9 million, after deducting underwriting discounts and commissions and other offering expenses paid by the Company.

2012_Private_Placement_Former_

2012 Private Placement - Former Related Party	12 Months Ended
2012 Private Placement - Former Related Party	Dec. 31, 2014
Investments Schedule [Abstract]
Investment [Text Block]	19. 2012 Private Placement – Former Related Party

	On December 21, 2012, the Company, closed a $2,000,000 private placement (the “Offering”) with Amzak Capital Management, LLC (the “Investor”). Pursuant to the terms of a Securities Purchase Agreement entered into with the Investor (the “Purchase Agreement”) on December 20, 2012, the Company issued to the Investor (i) 1,965,740 shares of the Company common stock, held in treasury (the “Shares”), and (ii) a ten-year warrant to purchase up to an aggregate of 387,201 shares of the Company common stock, with an exercise price of $0.01 per share (the “Warrants”). The Warrants are exercisable immediately. The Company used the proceeds from this Offering to for general working capital as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013.

	In connection with the Offering, the Company also entered into a registration rights agreement (the “Registration Rights Agreement ”), dated as of December 20, 2012, with the Investor, relating to the registration of the Shares, the Warrants and the shares of common stock issuable upon the exercise of the Warrants, issued in connection with the Offering (the “ Registrable Shares ”). The Registration Rights Agreement provides that the Company will file a “resale” registration statement (the “Initial Registration Statement”) covering all of the Registerable Shares within six months of the date of the Registration Rights Agreement and that such Initial Registration Statement shall be declared effective within nine months of the date of the Registration Rights Agreement, subject to certain limitations. Further, the Company has agreed to pay the Investor specified cash payments as partial liquidated damages in the event the Initial Registration Statement is not declared effective by the Securities and Exchange Commission (the “SEC”) within the specified timeframe. The Initial Registration Statement was filed with the SEC on May 9, 2013, within six months of the date of the Registration Rights Agreement and became effective on May 13, 2013, within nine months of the date of the Registration Rights Agreement.

Asset_Purchase_Agreements

Asset Purchase Agreements	12 Months Ended
Asset Purchase Agreements	Dec. 31, 2014
Asset Purchase Agreement Disclosure [Abstract]
Asset Purchase Agreement Disclosure [Text Block]	20. Asset Purchase Agreements

	Prasco

	On February 1, 2013, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Prasco, LLC, an Ohio limited liability company (“Prasco”), pursuant to which the Company purchased from Prasco assets associated with econazole nitrate cream 1% (the “Product” ), which is available in 15g, 30g, and 85g tubes and has United States Food and Drug Administration approved indications for the treatment of tinea pedis, tinea cruris, and tinea corporis as well as the treatment of cutaneous candidiasis and tinea versicolor.

	In consideration for the purchase of the assets pursuant to the Purchase Agreement, the Company paid Prasco $1.4 million in cash and paid an additional aggregate of $400,000 upon the occurrence of the milestone events (the “Milestone Payment”). The Milestone Payment is secured by a first-priority security interest in the acquired assets under the Purchase Agreement. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment, milestone payment and related costs to acquire the asset are included as part of product acquisition costs totaling $1.8 million. The Company is amortizing the costs over fifteen years (approximately $120,000 per year), the useful life of the acquired product and product rights.

	Under and subject to the terms and conditions of the Purchase Agreement, Prasco continued to distribute the Product during a six-month period following the closing of the Purchase Agreement, and the Company completed the technical transfer of the Product and begun manufacturing and selling the Product under its own label during the third quarter of 2013.

	In addition, the Purchase Agreement contains certain non-compete restrictions preventing Prasco from selling the Product in United States for a period of seven years.

	On October 23, 2013, the Company announced that it had received formal approval from the U.S. Food and Drug Administration (FDA) for the CBE-30 supplemental filing to approve the site transfer of the Econazole nitrate cream 1%, to the Company’s manufacturing facility in Buena, NJ.

	Astra Zeneca

	On September 24, 2014, the Company entered into an Asset Purchase Agreement (the “AZ Purchase Agreement”) with AstraZeneca Pharmaceuticals LP, a Delaware corporation (“AstraZeneca”), pursuant to which the Company acquired all rights, titles and interests of AstraZeneca and its affiliates in Abbreviated New Drug Applications and New Drug Applications associated with eighteen products (collectively the “Purchased Regulatory Approvals”) and certain documents relating thereto (together with the Purchased Regulatory Approvals, the “Purchased Assets ”).

	In consideration for the purchase of the Purchased Assets, the Company paid AstraZeneca $500,000 in cash and will be required to pay up to an additional aggregate of $6,000,000 upon the occurrence of a certain milestone event. The $6,000,000 is accrued at December 31, 2014 in the payable for product acquisition costs. In addition, the Company has agreed to pay, for each product manufactured by the Company pursuant to a Purchased Regulatory Approval, a royalty on future gross profits from product sales. Notwithstanding the foregoing, at any time prior to December 1, 2015, the Company may satisfy in full its royalty obligations with a single payment of $3,000,000. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment, milestone payment and related costs to acquire the asset are included as part of product acquisition costs totaling $6,910,000. The Company and will amortize the costs over fifteen years, the useful life of the acquired products and product rights, commencing when the product can be sold.

	Valeant

	On September 30, 2014, the Company entered into two Asset Purchase Agreements (each, a “Valeant Purchase Agreement” and together, the “Valeant Asset Purchase Agreements”) one with Valeant Pharmaceuticals North America LLC and one with Valeant Pharmaceuticals Luxembourg SARL (together, “Valeant”), pursuant to which the Company acquired all rights, titles and interests of Valeant and their respective affiliates in Abbreviated New Drug Applications and New Drug Applications associated with two products (collectively, the “Valeant Purchased Regulatory Approvals”) and certain documents relating thereto (together with the Valeant Purchased Regulatory Approvals, the “Valeant Purchased Assets”). Pursuant to the terms of the Valeant Asset Purchase Agreements, the Company also acquired the option (each, an “Option” and, collectively, the “Options”) to purchase Abbreviated New Drug Applications and New Drug Applications associated with three additional products (the “Additional Assets”).

	In consideration for the purchase of the Valeant Purchased Assets, the Company paid Valeant an aggregate of $1,500,000 in cash. In consideration for the purchase of the Additional Assets, the Company may exercise any Option, in its sole discretion, and pay $750,000 for each of two additional products and $500,000 for one additional product, for a total aggregate of $2,000,000 if all Options are exercised. The Company purchased the one additional product for $500,000 on November 18, 2014. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment and related costs to acquire the Valeant Purchased Assets are included as part of product acquisition costs totaling $2,048,000. The Company will amortize the costs over fifteen years, the useful life of the acquired product and product rights, commencing when the product can be sold.

Quarterly_Results

Quarterly Results	12 Months Ended
Quarterly Results	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	Quarterly Results (Unaudited)

	The following is a summary of certain quarterly financial information for fiscal years 2014 and 2013:

		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter		Total
	(in thousands, except per share data)
	Year Ended December 31, 2014
	Total revenues, net		6,853		6,483		6,668		13,736		33,740
	Gross profit		2,866		2,903		2,632		8,391		16,792
	Operating income (loss)		219		-281		-144		4,112		3,906
	Net income (loss)		167		-345		-202		5,631		5,251
	Net income (loss) attributable to common stockholders		167		-345		-202		5,631		5,251
	Basic income (loss) per share	$	0	$	-0.01	$	0	$	0.11	$	0.11
	Diluted income (loss) per share	$	0	$	-0.01	$	0	$	0.09	$	0.09

	Year Ended December 31, 2013
	Total revenues, net		3,683		3,820		3,995		6,726		18,224
	Gross profit		1,108		1,147		1,311		2,579		6,145
	Operating (loss) income		-229		-364		-42		553		-82
	Net (loss) income		-257		-403		-95		671		-84
	Net loss attributable to common stockholders		-257		-403		-95		-637		-1,392
	Basic loss per share	$	-0.01	$	-0.01	$	0	$	-0.01	$	0.03)
	Diluted loss per share	$	-0.01	$	-0.01	$	0	$	-0.01	$	0.03)

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)

				Additions

		Balance at		Charged to		Charged
		Beginning		Costs and		other				Balance at
		of Year		Expenses		Accounts		Deductions		End of Year
	Year Ended December 31, 2013
	Valuation Allowance for Deferred Tax Assets	$	12,358		--		--		-296	$	12,062
	Year Ended December 31, 2014
	Fair Value of Convertible Feature of Convertible 3.75% Senior Notes	$	--		--		43,700		-2,300	$	41,400
	Valuation Allowance for Deferred Tax Assets	$	12,062		--		--		-1,092	$	10,970

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Business Description and Basis of Presentation [Text Block]

Nature of the Business

Currently, the Company has two platforms for growth:

•

Developing, manufacturing, and marketing a portfolio of generic pharmaceutical products under our own label in topical, injectable, complex and ophthalmic dosage forms; and,

•

Managing our current contract manufacturing and formulation services business.

On February 1, 2013, we acquired assets and intellectual property, including an ANDA, for econazole nitrate cream 1%, which we launched in September 2013.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2014:

Fair value measurement at reporting date using

Quoted prices in

Significant

active markets for

other

Significant

identical assets

observable

unobservable

Derivative liabilites on account of convertible notes

Balance

(Level 1)

inputs (Level 2)

inputs (Level 3)

As of December 31, 2014

41,400

Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]

Accounts Receivable and Allowance for Doubtful Accounts

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Inventory, Policy [Policy Text Block]

Inventories

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows:

Useful Lives

Buildings and improvements

10 - 30 years

Machinery and equipment

3 - 10 years

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Intangible assets consist of the cost of an acquired product and product rights. Intangible assets are amortized over fifteen years (the asset’s estimated useful life).

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Long-Lived Assets

Loans and Leases Receivable, Nonaccrual Loan and Lease Status, Policy [Policy Text Block]

Accrued Expenses

Revenue Recognition, Services, Licensing Fees [Policy Text Block]

License Fee

License fees are amortized on a straight-line basis over the life of the agreement (10 years).

Environmental Costs, Policy [Policy Text Block]

Accounting for Environmental Costs

Income Tax, Policy [Policy Text Block]

Income Taxes

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.

Revenue and Provision for Sales Returns and Allowances

Gross-To-Net Sales Deductions

Years Ended December 31,

2014

2013

2012

(in thousands)

Gross IGI product sales

51,136

15,001

Reduction to gross product sales:

Chargebacks and billbacks

-26,940

-6,050

Sales discounts and other allowances

-4,366

-1,593

-1

Total reduction to gross product sales

-31,306

-7,643

-1

Net IGI product sales

19,830

7,358

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

Debt, Policy [Policy Text Block]

Debt Issuance Costs

Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan. See detailed amounts per year in Notes 6, 7 and 8.

Research, Development, and Computer Software, Policy [Policy Text Block]

Product Development and Research

The Company's research and development costs are expensed as incurred.

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling Costs

Costs related to shipping and handling is comprised of outbound freight and the associated labor. These costs are recorded in costs of sales.

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) per Common Share

For the years ended December 31, 2014, 2013 and 2012

(in thousands except shares and per share data)

2014

2013

2012

Basic earnings per share computation:

Net income (loss) attributable to common stockholders —basic

5,251

-1,392

-3,927

Weighted average common shares —basic

49,817,721

43,517,640

39,786,446

Basic net income (loss) per share

0.11

-0.03

-0.1

Dilutive earnings per share computation:

Net income (loss) attributable to common stockholders —basic

5,251

-1,392

-3,927

Interest expense related to convertible 3.75% senior notes

224

Net income (loss) attributable to common stockholders —diluted

5,475

-1,392

-3,927

Share Computation:

Weighted average common shares —basic

49,817,721

43,517,640

39,786,446

Effect of convertible 3.75% senior notes

12,732,168

Effect of dilutive stock options and warrants

1,657,301

Weighted average common shares outstanding —diluted

64,207,190

43,517,640

39,786,446

Diluted net income (loss) per share

0.09

-0.03

-0.1

Derivatives, Policy [Policy Text Block]

Derivatives

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2014:

				Fair value measurement at reporting date using
					Quoted prices in		Significant
					active markets for		other		Significant
					identical assets		observable		unobservable
	Derivative liabilites on account of convertible notes	Balance			(Level 1)		inputs (Level 2)		inputs (Level 3)
	As of December 31, 2014	$	41,400			-		-	$	41,400

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Gross-To-Net Sales Deductions

		Years Ended December 31,
		2014			2013		2012
		(in thousands)

	Gross IGI product sales	$	51,136		$	15,001	$	18
	Reduction to gross product sales:
	Chargebacks and billbacks		-26,940			-6,050		__
	Sales discounts and other allowances		-4,366			-1,593		-1
	Total reduction to gross product sales	$	-31,306		$	-7,643	$	-1

	Net IGI product sales	$	19,830		$	7,358	$	17

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	As of December 31, 2013, the shares of common stock issuable in connection with stock options and warrants of 2,998,406, and as of December 31, 2012, the shares of common stock issuable in connection with stock options and warrants and the conversion of preferred stock of 6,445,628 were not included in the diluted income per common share calculation since their effect was anti-dilutive.

	For the years ended December 31, 2014, 2013 and 2012
	(in thousands except shares and per share data)

		2014			2013		2012
	Basic earnings per share computation:
	Net income (loss) attributable to common stockholders —basic	$	5,251		$	-1,392	$	-3,927
	Weighted average common shares —basic		49,817,721			43,517,640		39,786,446
	Basic net income (loss) per share	$	0.11		$	-0.03	$	-0.1

	Dilutive earnings per share computation:
	Net income (loss) attributable to common stockholders —basic	$	5,251		$	-1,392	$	-3,927
	Interest expense related to convertible 3.75% senior notes		224			-		-
	Net income (loss) attributable to common stockholders —diluted	$	5,475		$	-1,392	$	-3,927
	Share Computation:
	Weighted average common shares —basic		49,817,721			43,517,640		39,786,446
	Effect of convertible 3.75% senior notes		12,732,168			-		-
	Effect of dilutive stock options and warrants		1,657,301			-		-
	Weighted average common shares outstanding —diluted		64,207,190			43,517,640		39,786,446
	Diluted net income (loss) per share	$	0.09		$	-0.03	$	-0.1

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories as of December 31, 2014 and 2013 consisted of:

		2014		2013
		(in thousands)

	Raw materials	$	2,299	$	2,172
	Work in progress		140		271
	Finished goods		345		426
		$	2,784	$	2,869

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment, at cost, as of December 31, 2014 and 2013, consisted of:

		2014		2013
		(in thousands)

	Land	$	257	$	257
	Building and improvements		3,775		3,599
	Machinery and equipment		4,156		3,375
	Construction in progress		225		128
			8,413		7,359
	Less accumulated depreciation and amortization		-5,151		-4,736

	Property, plant and equipment, net	$	3,262	$	2,623

Convertible_375_Senior_Notes_T

Convertible 3.75% Senior Notes (Tables)	12 Months Ended
Convertible 3.75% Senior Notes (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Convertible Debt [Table Text Block]	At December 31, 2014 the net carrying amount of the liability component and the remaining unamortized debt discount were as follows:

			December 31,
			2014
			(in thousands)

	Face Amount of the Notes		$	143,750
	Unamortized discount of the liability component			43,439
	Carrying amount of the Notes		$	100,311

Schedule of Long-term Debt Instruments [Table Text Block]	The assumptions used in connection with the valuation of the convertible option of the Notes issued December 16, 2014 utilizing the "with” and “without” method, discussed in Note 2 was as follows:

			Initial Measurement				Measurement
			December 16,				December 31,
			2014				2014
	Issue date			12/17/14				12/17/14
	Maturity date			12/15/19				12/15/19
	Term			4.99				4.92
	Principal (millions)			143.75				143.75
	Coupon			3.75	%			3.75	%
	Seniority			Senior unsecured				Senior unsecured
	Conversion shares			88.572				88.572
	Conversion price		$	11.29			$	11.29

	Stock price		$	9.45			$	8.8
	Risk free rate			1.61	%			1.64	%

	Volatily (rounded)			40	%			40	%

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The table below provides a reconciliation of beginning and ending balances for the liability measured at fair value using significant observable and unobservable inputs (Level 3). The table reflects the gain for the year ended December 31, 2014 associated with the decrease in fair value.

			Initial
			Measurement
			December 16,			Decrease in			December 31,
			2014			Fair Value			2014
	Fair Value of Convertible Feature of Convertible 3.75% Senior Notes		$	43,700		$	2,300		$	41,400

Interest Income and Interest Expense Disclosure [Table Text Block]	For the year ended December 31, 2014, the Company recorded the following expenses in relation to the Notes:

			December 31,
			2014
			(in thousands)

	Interest Expense at 3.75% coupon rate		$	225
	Debt Discount Amortization			261
	Amortization of deferred financing costs			28
	Total interest expense (1)		$	514

		-1	Included within “Interest and other expense, net” on the Consolidated Statements of Operations

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumptions	2014			2013			2012

	Dividend yield		0	%		0	%		0	%
	Risk free interest rate		0.74% - 1.2	%		0.48	%		0.39	%
	Estimated volatility factor		44.0% - 53.0	%		36.9% – 43.1	%		54.5	%
	Expected life		3.2 – 3.3 years			3.2 – 3.3 years			3.2 years

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]					Exercise			Weighted Average
		Shares			Price Per Share			Exercise Price
	January 1, 2012 shares issuable under options		1,448,016		$	.55 - 1.74		$	1.16
	Granted		1,551,000			1.02 - 1.18			1.05
	Exercised		-40,000			0.65			0.65
	Expired		-15,000			0.65			0.65
	Forfeited		-337,516			.55 - 1.52			1.22
	December 31, 2012 shares issuable under options		2,606,500			.55 - 1.74			1.1
	Granted		247,000			1.04 - 3.03			1.35
	Exercised		-129,336			1.02 - 1.27			1.08
	Expired		—			—			—
	Forfeited		-80,664			1.10 - 1.74			1.3
	December 31, 2013 shares issuable under options		2,643,500			.55 - 3.03			1.12
	Granted		397,500			2.96 – 10.55			5.89
	Exercised		-443,166			.55 – 1.95			1.15
	Expired		—
	Forfeited		-161,000			1.00 – 5.65			2.71
	December 31, 2014 shares issuable under options		2,436,834			0.76 – 10.55			1.79

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2014:

		Options Outstanding									Options Exercisable
					Weighted			Weighted					Weighted
					Average			Average					Average
	Range of	Number of			Remaining			Exercise			Number of		Exercise
	Exercise Price	Options			Life (Years )			Price			Options		Price

	$ 0.76 to $ 1.00		97,000			3.04		$	0.78			97,000	$	0.78
	1.01 to 1.50		1,887,500			7.14			1.07			1,448,664		1.08
	1.51 to 10.55		452,334			8.68			5.02			110,333		1.78

	$0.76 to $10.55		2,436,834			7.26		$	1.79			1,655,997	$	1.11

	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2013:

		Options Outstanding									Options Exercisable
					Weighted			Weighted					Weighted
					Average			Average					Average
	Range of	Number of			Remaining			Exercise			Number of		Exercise
	Exercise Price	Options			Life (Years )			Price			Options		Price

	$.55 to $1.00		218,000			4.83		$	0.76			214,000	$	0.75
	1.01 to 2.00		2,418,000			7.9			1.14			1,238,496		1.19
	2.01 to 3.03		7,500			9.87			2.83			—		—

	$.55 to $3.03		2,643,500			7.65		$	1.12			1,452,496	$	1.13


	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2012:

		Options Outstanding									Options Exercisable
					Weighted			Weighted					Weighted
					Average			Average					Average
	Range of	Number of			Remaining			Exercise			Number of		Exercise
	Exercise Price	Options			Life (Years )			Price			Options		Price

	$.55 to $1.00		218,000			5.83		$	0.76			212,000	$	0.75
	1.01 to 1.50		2,213,500			8.43			1.09			564,001		1.21
	1.51 to 1.74		175,000			8.01			1.68			175,000		1.68

	$.55 to $1.74		2,606,500			8.19		$	1.1			951,001	$	1.19

Nonvested Restricted Stock Shares Activity [Table Text Block]					Weighted Average
		Options			Grant Date Fair Value

	Non-vested options at January 1, 2014		1,191,004		$	0.33
	Granted		397,500			2.09
	Vested		-665,333			0.32
	Forfeited		-142,334			0.87
	Non-vested options at December 31, 2014		780,837		$	1.12

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]		Number of			Weighted Average
		Restricted Stock			Issuance Price

	Non-vested balance at January 1, 2012		626,000		$	0.71

	Changes during the period:
	Shares granted		109,748			1
	Shares vested		-529,330			0.76
	Shares forfeited		-177,084			0.7
	Non-vested balance at January 1, 2013		29,334		$	1

	Changes during the period:
	Shares granted		325,000			2.86
	Shares vested		-108,333			2.86
	Shares forfeited		—
	Non-vested balance at December 31, 2013		246,001		$	2.64

	Changes during the period:
	Shares granted		-
	Shares vested		-137,667			2.46
	Shares forfeited		-
	Non-vested balance at December 31, 2014		108,334		$	2.86

Stock_Warrants_Tables

Stock Warrants (Tables)	12 Months Ended
Stock Warrants (Tables)	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Stock Warrants as of December 31, 2014, 2013 and 201 consisted of:

		2014				2013				2012
				Weighted				Weighted				Weighted
				Average				Average				Average
		Warrants		Exercise Price		Warrants		Exercise Price		Warrants		Exercise Price

	Beginning balance		354,546	$	1.21		782,259	$	0.85		1,235,877	$	0.35

	Stock warrants granted		—		—		—		—		814,914		0.29
	Stock warrants expired		—		—		—		—		—		—
	Stock warrants exercised		-270,546		1.21		-427,713		0.55		-1,268,532		0.01

	Ending balance		84,000	$	1.21		354,546	$	1.21		782,259	$	0.85

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		2014		2013		2012
		(in thousands)
	Current tax expense (benefit):
	Federal	$	97	$	-	$	-
	State and local		76		-197		-184
	Total current tax expense (benefit)		173		-197		-184
	Deferred tax expense (benefit):
	Federal		-		-		-
	State and local		-		-		-
	Total deferred tax expense (benefit)		-		-		-
	Total income tax expense (benefit)	$	173	$	-197	$	-184

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014		2013		2012
		(in thousands)
	Expected Statutory expense (benefit)	$	1,844	$	-95	$	-1,381

	Gain on derivative and amortization of debt discount		-693		-		-
	Other non-deductible expenses		3		2		1
	Change in valuation allowance		-1,031		30		1317
	Sale of New Jersey net operating losses		-		-197		-189
	State income taxes, net of federal benefit		50		-
	Federal tax impact of state tax benefit, net		-		63		68
		$	173	$	-197	$	-184

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax assets included in the Consolidated Balance Sheets as of December 31, 2014 and 2013 consisted of the following:

		2014		2013
		(in thousands)
	Current Assets:
	Reserves and allowances	$	40	$	121

	Other		647		161
	Total current assets		687		282
	Long Term Assets (Liabilities):
	Property, plant and equipment basis difference		245		209
	Net operating loss carry forwards		9,068		10,672
	Tax credit carry forwards		293		217
	Non-employee stock options		682		685
	Other		-5		-3
	Total Long Term Assets,net		10,283		11,780
	Gross Deferred Tax Asset, net		10,970		12,062
	Less Valuation Allowance		-10,970		-12,062
	Deferred taxes, net	$	-	$	-

Summary of Operating Loss Carryforwards [Table Text Block]	Operating loss and tax credit carry forwards as of December 31, 2014 were as follows:

		2014		2013
		(in thousands)
	Federal:
	Net operating losses	$	26,602	$	31,308
	Research tax credits (expiring through 2025)		168		168
	Alternative minimum tax credits (available without expiration)		123		28
	State:
	Net operating losses - Tennessee (expiring in 2027)		322		425
	Alternative minimum tax assessment - New Jersey (available without expiration)		1		21

Summary Of Operating Loss Carry forwards Expire [Table Text Block]	At December 31, 2014, the Company’s U.S. federal net operating loss carryforwards will expire as follows:

	Year	Net Operating Loss
		(in thousands)

	2020	$	5,225
	2021		1,157
	2022		-
	2023		1,232
	2024		974
	2025		1,850
	2026		1,070
	2027		308
	2028		1,414
	2029		3,447
	2030		3,455
	2031		2,749
	2032		3,721

	Total	$	26,602

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
Lease Commitments (Tables)	Dec. 31, 2014
Leases [Abstract]
Operating Leases of Lessee Disclosure [Table Text Block]	Future minimum lease payments under non-cancelable operating leases are as follows:

		Amount
	Years Ending December 31,
	2015	$	278,000
	2016		418,000
	2017		410,000
	2018		348,000
	2019		318,000
	Thereafter		1,168,000
	Total	$	2,940,000

Quarterly_Results_Tables

Quarterly Results (Tables)	12 Months Ended
Quarterly Results (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	The following is a summary of certain quarterly financial information for fiscal years 2014 and 2013:

		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter		Total
	(in thousands, except per share data)
	Year Ended December 31, 2014
	Total revenues, net		6,853		6,483		6,668		13,736		33,740
	Gross profit		2,866		2,903		2,632		8,391		16,792
	Operating income (loss)		219		-281		-144		4,112		3,906
	Net income (loss)		167		-345		-202		5,631		5,251
	Net income (loss) attributable to common stockholders		167		-345		-202		5,631		5,251
	Basic income (loss) per share	$	0	$	-0.01	$	0	$	0.11	$	0.11
	Diluted income (loss) per share	$	0	$	-0.01	$	0	$	0.09	$	0.09

	Year Ended December 31, 2013
	Total revenues, net		3,683		3,820		3,995		6,726		18,224
	Gross profit		1,108		1,147		1,311		2,579		6,145
	Operating (loss) income		-229		-364		-42		553		-82
	Net (loss) income		-257		-403		-95		671		-84
	Net loss attributable to common stockholders		-257		-403		-95		-637		-1,392
	Basic loss per share	$	-0.01	$	-0.01	$	0	$	-0.01	$	0.03)
	Diluted loss per share	$	-0.01	$	-0.01	$	0	$	-0.01	$	0.03)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	$41,400	$0
Fair Value, Inputs, Level 1 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	0
Fair Value, Inputs, Level 2 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	0
Fair Value, Inputs, Level 3 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	$41,400

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
Summary of Significant Accounting Policies (Details 1)	Dec. 31, 2014
Building and Building Improvements [Member] \| Minimum [Member]
Summary of Significant Accounting Policies Details Depreciation of Property Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Building and Building Improvements [Member] \| Maximum [Member]
Summary of Significant Accounting Policies Details Depreciation of Property Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Machinery and Equipment [Member] \| Minimum [Member]
Summary of Significant Accounting Policies Details Depreciation of Property Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Summary of Significant Accounting Policies Details Depreciation of Property Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross IGI product sales	$51,136,000	$15,001,000	$18,000
Reduction to gross product sales:
Chargebacks and billbacks			0
Net IGI product sales	32,104,000	16,981,000	6,545,000
Gross Net Adjustments [Member]
Reduction to gross product sales:
Chargebacks and billbacks	-26,940,000	-6,050,000
Sales discounts and other allowances	-4,366,000	-1,593,000	-1,000
Total reduction to gross product sales	-31,306,000	-7,643,000	-1,000
Net IGI product sales	$19,830,000	$7,358,000	$17,000

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basic earnings per share computation:
Net income (loss) attributable to common stockholders Â—basic	$5,631	($202)	($345)	$167	($637)	($95)	($403)	($257)	$5,251	($1,392)	($3,927)
Weighted average common shares Â—basic									49,817,721	43,517,640	39,786,446
Basic net income (loss) per share	$0.11	$0	($0.01)	$0	($0.01)	$0	($0.01)	($0.01)	$0.11	($0.03)	($0.10)
Dilutive earnings per share computation:
Net income (loss) attributable to common stockholders Â—basic	5,631	-202	-345	167	-637	-95	-403	-257	5,251	-1,392	-3,927
Interest expense related to convertible 3.75% senior notes									224	0	0
Net income (loss) attributable to common stockholders Â—diluted									$5,475	($1,392)	($3,927)
Share Computation:
Weighted average common shares Â—basic									49,817,721	43,517,640	39,786,446
Effect of convertible 3.75% senior notes									12,732,168	0	0
Effect of dilutive stock options and warrants									1,657,301	0	0
Weighted average common shares outstanding Â—diluted									64,207,190	43,517,640	39,786,446
Diluted net income (loss) per share	$0.09	$0	($0.01)	$0	($0.01)	$0	($0.01)	($0.01)	$0.09	($0.03)	($0.10)

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 16, 2014
Summary of Significant Accounting Policies Details [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)		2,998,406	6,445,628
Accounts Payable and Accrued Liabilities	$1,700,000	$600,000
WholeSale Fees	3,100,000	900,000	0
Royalty Expense	3,600,000	2,600,000	0
Accrued Salaries	1,400,000	700,000
Accrued Royalties	700,000	900,000
Inventory Valuation Reserves	200,000	200,000
Interest Payable	200,000
Unrealized Gain (Loss) on Derivatives	2,300,000	0	0
Convertible Notes Payable [Member]
Summary of Significant Accounting Policies Details [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.75%			3.75%
Notes Payable, Fair Value Disclosure	141,500,000
Long-term Debt, Gross	143,750,000
Unrealized Gain (Loss) on Derivatives	2,300,000
Finite-Lived Intangible Assets, Amortization Method	straight-line basis
Finite-Lived Intangible Asset, Useful Life	10 years
Licensing Agreements [Member]
Summary of Significant Accounting Policies Details [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Accounts Receivable [Member]
Summary of Significant Accounting Policies Details [Line Items]
Concentration Risk, Percentage	42.00%	11.00%	59.00%
Sales Revenue, Net [Member]
Summary of Significant Accounting Policies Details [Line Items]
Concentration Risk, Percentage	44.00%	39.00%	54.00%
Customer One [Member] \| Sales Revenue, Product Line [Member]
Summary of Significant Accounting Policies Details [Line Items]
Revenue, Net	10,500,000		2,800,000
Customer One [Member] \| Sales Revenue, Net [Member]
Summary of Significant Accounting Policies Details [Line Items]
Revenue, Net		2,800,000
Customer Two [Member] \| Sales Revenue, Product Line [Member]
Summary of Significant Accounting Policies Details [Line Items]
Revenue, Net	4,400,000		1,800,000
Customer Two [Member] \| Sales Revenue, Net [Member]
Summary of Significant Accounting Policies Details [Line Items]
Revenue, Net		2,200,000
Customer Three [Member] \| Sales Revenue, Net [Member]
Summary of Significant Accounting Policies Details [Line Items]
Revenue, Net		2,100,000
Product Concentration Risk [Member] \| Sales Revenue, Net [Member]
Summary of Significant Accounting Policies Details [Line Items]
Concentration Risk, Percentage	38.00%
Royalty [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accounts Payable and Accrued Liabilities	700,000	900,000
Consulting Fees [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accrued Professional Fees	300,000
Directors' fees [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accrued Professional Fees	100,000	200,000
Professional Fee [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accrued Professional Fees	1,700,000	600,000
Maximum [Member] \| Licensing Agreements [Member]
Summary of Significant Accounting Policies Details [Line Items]
Whole Saler Percent of Chargebacks	95.00%
Minimum [Member] \| Licensing Agreements [Member]
Summary of Significant Accounting Policies Details [Line Items]
Whole Saler Percent of Chargebacks	90.00%
Net Of SRA Balance [Member]
Summary of Significant Accounting Policies Details [Line Items]
Accounts Receivable, Net	$5,600,000	$1,900,000

Liquidity_Details_Textual

Liquidity (Details Textual) (USD $)	12 Months Ended
Liquidity (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 21, 2010	Dec. 16, 2014
Liquidity [Line Items]
Cash and Cash Equivalents, at Carrying Value	$158,883,000	$2,101,000	$2,536,000	$2,914,000
Line of Credit Facility, Remaining Borrowing Capacity	6,840,000
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000				3,000,000
Proceeds from Issuance of Senior Long-term Debt	138,985,000	0	0
Convertible Notes Payable [Member]
Liquidity [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.75%					3.75%
Proceeds from Issuance of Senior Long-term Debt	139,000,000
Payments of Debt Issuance Costs	$4,765,000

License_Fee_Details_Textual

License Fee (Details Textual) (Licensing Agreements [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 12, 2005
Licensing Agreements [Member]
License Fee [Line Items]
Finite-Lived License Agreements, Gross				$1,000,000
Finite-Lived Intangible Asset, Useful Life	10 years
Amortization	100,000	100,000	100,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$100,000

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw materials	$2,299	$2,172
Work in progress	140	271
Finished goods	345	426
Total	$2,784	$2,869

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	$8,413	$7,359
Less accumulated depreciation and amortization	-5,151	-4,736
Property, plant and equipment, net	3,262	2,623
Land [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	257	257
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	3,775	3,599
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	4,156	3,375
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment	$225	$128

Property_Plant_and_Equipment_D1

Property, Plant and Equipment (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation	$415	$375	$357

Convertible_375_Senior_Notes_D

Convertible 3.75% Senior Notes (Details) (Convertible Notes Payable [Member], USD $)	Dec. 31, 2014	Dec. 16, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 16, 2014
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Face Amount of the Notes	$143,750	$143,750
Unamortized discount of the liability component	43,439
Carrying amount of the Notes	$100,311

Convertible_375_Senior_Notes_D1

Convertible 3.75% Senior Notes (Details 1) (Convertible Notes Payable [Member], USD $)	0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 16, 2014	Dec. 31, 2014
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Issue date	17-Dec-14	17-Dec-14
Maturity date	15-Dec-19	15-Dec-19
Term	4 years 11 months 26 days	4 years 11 months 1 day
Principal (millions)	$143,750	$143,750
Coupon	3.75%	3.75%
Seniority	Senior unsecured	Senior unsecured
Conversion shares	88.572	88.572
Conversion price	$11.29	$11.29
Stock price	$9.45	$8.80
Risk free rate	1.61%	1.64%
Volatily (rounded)	40.00%	40.00%

Convertible_375_Senior_Notes_D2

Convertible 3.75% Senior Notes (Details 2) (Convertible Notes Payable [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Fair Value of Convertible Feature of Convertible 3.75% Senior Notes, Initial Measurement December 16, 2014	$43,700
Fair Value of Convertible Feature of Convertible 3.75% Senior Notes, Decrease in Fair Value	2,300
Fair Value of Convertible Feature of Convertible 3.75% Senior Notes, December 31, 2014	$41,400

Convertible_375_Senior_Notes_D3

Convertible 3.75% Senior Notes (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Interest Expense at 3.75% coupon rate	($224)		$0	$0
Debt Discount Amortization	261		0	0
Amortization of deferred financing costs	107		31	862
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Interest Expense at 3.75% coupon rate	225
Debt Discount Amortization	261
Amortization of deferred financing costs	28
Total interest expense (1)	$514	[1]

[1]	Included within â€œInterest and other expense, netâ€ on the Consolidated Statements of Operations

Convertible_375_Senior_Notes_D4

Convertible 3.75% Senior Notes (Details Textual) (USD $)	12 Months Ended
Convertible 3.75% Senior Notes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 22, 2014	Dec. 16, 2014
Debt Instrument [Line Items]
Proceeds from Issuance of Senior Long-term Debt	$138,985,000	$0	$0
Interest Payable	200,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				18,750,000	125,000,000
Proceeds from Issuance of Senior Long-term Debt	139,000,000
Payments of Debt Issuance Costs	4,800,000
Interest Payable	$200,000
Debt Instrument, Period of Debt Discount and Financing Costs Amortization	4 years 11 months 12 days
Debt Instrument, Convertible, Terms of Conversion Feature	The Notes are convertible at an initial conversion price of approximately $11.29 per share, which is equivalent to an initial conversion rate of 88.5716 shares per $1,000 principal amount of Notes, subject to adjustment in certain events, such as distributions of dividends or stock splits. Holders may convert their Notes at their option prior to September 15, 2019, when or if certain conditions have been met or circumstances have occurred, such as the Companys stock price exceeds 130% of the conversion price under the Notes for a designated period of time, or the trading price of the Notes is, for a designated period of time, less than 98% of the closing sale price of the Companys common stock multiplied by the then-current conversion rate of the Notes, or the Company calls Notes for redemption, or certain specified corporate events occur. Holders may also convert their Notes at their option at any time on or after September 15, 2019 and prior to the close of business on the business day immediately preceding the stated maturity date.

Note_Payable_General_Electric_1

Note Payable - General Electric Capital Corporation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$6,840,000
General Electric Capital Corporation [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Amount Outstanding During Period	10,000,000
Line of Credit Facility, Current Borrowing Capacity	10,000,000
Line of Credit Facility, Interest Rate Description	Borrowings under the Credit Agreement may be made as prime rate loans with an applicable margin of 3.0% per annum or 1, 2, 3 or 6 month LIBOR loans with an applicable margin of 4.0% per annum.
Line of Credit Facility, Interest Rate at Period End	4.00%
Availability of Credit, Percentage on Book Value	85.00%
Long-term Line of Credit	3,160,000
Line of Credit Facility, Remaining Borrowing Capacity	6,744,000
Line of Credit Facility, Interest Rate During Period	4.20%
Line Of Credit Margin Percentage	3.00%
Line of Credit Facility, Expected Maximum Borrowing Capacity	$15,000,000

Note_Payable_Square_1_Bank_Det

Note Payable - Square 1 Bank (Details Textual) (Square 1 Bank Loan [Member], USD $)	0 Months Ended		1 Months Ended	12 Months Ended
	Aug. 02, 2013	Feb. 05, 2013	Aug. 31, 2012	Dec. 31, 2014
Square 1 Bank Loan [Member]
Note Payable [Line Items]
Proceeds from Lines of Credit	$1,000,000	$1,000,000	$1,000,000
Write off of Deferred Debt Issuance Cost				$42,000

Note_Payable_Former_Related_Pa1

Note Payable - Former Related Party (Details Textual) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended
	Aug. 31, 2012	Dec. 31, 2012	Jul. 01, 2012	Dec. 21, 2010	Dec. 31, 2014	Sep. 28, 2012
Related Party Transaction [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				3,000,000	$10,000,000
Amortization of Deferred Charges	545,000	639,000
Interest Expense	545,000
Debt Issuance Cost		209,000
Credit Agreement [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					14.00%
Amzak Capital Management, LLC [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				427,713
Warrant Issuedin Connection with Credit Agreement [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				881,331
Number of Years		10 years
Initial Warrant Shares [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						881,331
Warrants and Rights Outstanding			$724,000
Percent of Fully Diluted Shares				1.00%
Number of Years			5 years
In Connection with Common Stock Purchase [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				0.55
Terms of Warrant [Member]
Related Party Transaction [Line Items]
Number of Years				10 years

Series_A_Convertible_Preferred1

Series A Convertible Preferred Stock (Details Textual) (USD $)	0 Months Ended
	Dec. 05, 2009	Dec. 05, 2007	Dec. 31, 2014	Dec. 31, 2013	Sep. 05, 2013
Series A Convertible Preferred Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion		10,000
Preferred Stock, Par or Stated Value Per Share		$0.01
Preferred Stock, Shares Authorized		1,000,000	1,000,000
Common Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Share Price		$2.50
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		50
Convertible Preferred Stock, Shares Issued upon Conversion		10,000			500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		175,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$1.25
Class of Warrant or Right Upon Conversion Aggregate Consideration	$500,000
Preferred Stock, Redemption Price Per Share		$1
Preferred Stock, Par or Stated Value Per Share		$10,000	$0.01	$0.01	$1
Convertible Preferred Stock, Terms of Conversion		ten
Preferred Stock, Shares Authorized		100	100	100
Series A Convertible Preferred Stock [Member] \| Subscription Arrangement [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Liquidation Preference Per Share		$10,000

Series_C_Convertible_Preferred1

Series C Convertible Preferred Stock - 2010 Offering (Details Textual) (USD $)	0 Months Ended	1 Months Ended
	Dec. 06, 2013	Mar. 29, 2010	Dec. 31, 2014	Dec. 05, 2007	Dec. 31, 2013
Series C Convertible Preferred Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share				$0.01
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Series C Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Line Items]
Stock Issued During Period, Shares, New Issues		1,550
Preferred Stock, Par or Stated Value Per Share		$0.01	0.01		$0.01
Preferred Stock, Dividend Rate, Percentage		5.00%
Preferred Stock, Call or Exercise Features		1,000
Preferred Stock, Shares Authorized			1,550		1,550
Preferred Stock and Accrued Dividends on Stock Converted	2,661,494
Convertible Preferred Stock, Terms of Conversion	Furthermore, each share of Series C Convertible Preferred Stock was convertible into shares of common stock equal to (i) 1,000 plus any accrued and unpaid dividends, divided by (ii) $0.69 (the closing price of the Company’s common stock on the date of issuance of the Series C Convertible Preferred Stock).
Common Stock, Closing Price Per Share		$0.69
Preferred Stock, Accrued Dividend	$1,308,000
Preferred Stock, Shares Issued			0		0
Series C Offering [Member]
Series C Convertible Preferred Stock [Line Items]
Proceeds from Issuance of Private Placement		$1,550,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details)	12 Months Ended
Stock-Based Compensation (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Based Compensation [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Risk free interest rate		0.48%	0.39%
Estimated volatility factor			54.50%
Expected life (years)			3 years 2 months 12 days
Minimum [Member]
Stock Based Compensation [Line Items]
Risk free interest rate	0.74%
Estimated volatility factor	44.00%	36.90%
Expected life (years)	3 years 2 months 12 days	3 years 2 months 12 days
Maximum [Member]
Stock Based Compensation [Line Items]
Risk free interest rate	1.20%
Estimated volatility factor	53.00%	43.10%
Expected life (years)	3 years 3 months 18 days	3 years 3 months 18 days

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Based Compensation [Line Items]
Number of Options Outstanding	2,643,500	2,606,500	1,448,016
Weighted Average Exercise Price Outstanding	$1.12	$1.10	$1.16
Number of Options Granted	397,500	247,000	1,551,000
Weighted Average Exercise Price Granted	$5.89	$1.35	$1.05
Number of Options Exercised	-443,166	-129,336	-40,000
Exercised, Exercise Price Per Share			$0.65
Weighted Average Exercise Price Exercised	$1.15	$1.08	$0.65
Number of Options Expired	0	0	-15,000
Expired, Exercise Price Per Share			$0.65
Weighted Average Exercise Price Expired		$0	$0.65
Number of Options Forfeited	-161,000	-80,664	-337,516
Weighted Average Exercise Price Forfeited	$2.71	$1.30	$1.22
Number of Options Outstanding	2,436,834	2,643,500	2,606,500
Weighted Average Exercise Price Outstanding	$1.79	$1.12	$1.10
Minimum [Member]
Stock Based Compensation [Line Items]
Shares Issuable Under Options Exercise Price Per Share			0.55
Granted, Exercise Price Per Share	$2.96	$1.04	$1.02
Exercised, Exercise Price Per Share	$0.55	$1.02
Forfeited, Exercise Price Per Share	1	1.1	0.55
shares issuable under options Exercise Price Per Share	$0.76	$0.55	$0.55
Maximum [Member]
Stock Based Compensation [Line Items]
Shares Issuable Under Options Exercise Price Per Share			1.74
Granted, Exercise Price Per Share	$10.55	$3.03	$1.18
Exercised, Exercise Price Per Share	$1.95	$1.27
Forfeited, Exercise Price Per Share	5.65	1.74	1.52
shares issuable under options Exercise Price Per Share	$10.55	$3.03	$1.74

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	12 Months Ended
Stock-Based Compensation (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	$0.76	$0.55	$0.55
Options Outstanding, Exercise Price Range, Upper Range Limit	$10.55	$3.03	$1.74
Options Outstanding, Number of Options	2,436,834	2,643,500	2,606,500
Options Outstanding, Weighted Average Remaining Contractual Term	7 years 3 months 4 days	7 years 7 months 24 days	8 years 2 months 8 days
Options Outstanding, Weighted Average Exercise Price	$1.79	$1.12	$1.10
Options Exercisable, Number of Options	1,655,997	1,452,496	951,001
Options Exercisable, Weighted Average Exercise Price	$1.11	$1.13	$1.19
Exercise Price Range, One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	$0.76	$0.55	$0.55
Options Outstanding, Exercise Price Range, Upper Range Limit	$1	$1	$1
Options Outstanding, Number of Options	97,000	218,000	218,000
Options Outstanding, Weighted Average Remaining Contractual Term	3 years 14 days	4 years 9 months 29 days	5 years 9 months 29 days
Options Outstanding, Weighted Average Exercise Price	$0.78	$0.76	$0.76
Options Exercisable, Number of Options	97,000	214,000	212,000
Options Exercisable, Weighted Average Exercise Price	$0.78	$0.75	$0.75
Exercise Price Range, Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	$1.01	$1.01	$1.01
Options Outstanding, Exercise Price Range, Upper Range Limit	$1.50	$2	$1.50
Options Outstanding, Number of Options	1,887,500	2,418,000	2,213,500
Options Outstanding, Weighted Average Remaining Contractual Term	7 years 1 month 20 days	7 years 10 months 24 days	8 years 5 months 5 days
Options Outstanding, Weighted Average Exercise Price	$1.07	$1.14	$1.09
Options Exercisable, Number of Options	1,448,664	1,238,496	564,001
Options Exercisable, Weighted Average Exercise Price	$1.08	$1.19	$1.21
Exercise Price Range, Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price Range, Lower Range Limit	$1.51	$2.01	$1.51
Options Outstanding, Exercise Price Range, Upper Range Limit	$10.55	$3.03	$1.74
Options Outstanding, Number of Options	452,334	7,500	175,000
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 8 months 5 days	9 years 10 months 13 days	8 years 4 days
Options Outstanding, Weighted Average Exercise Price	$5.02	$2.83	$1.68
Options Exercisable, Number of Options	110,333	0	175,000
Options Exercisable, Weighted Average Exercise Price	$1.78	$0	$1.68

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 3) (Non Vested [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Non Vested [Member]
Options, Non-vested options at January 1, 2014	1,191,004
Options, Granted	397,500
Options, Vested	-665,333
Options, Forfeited	$0.87
Options, Non-vested options at December 31, 2014	780,837
Weighted Average Grant Date Fair Value, Non-vested options at January 1, 2014	$0.33
Weighted Average Grant Date Fair Value, Granted	$2.09
Weighted Average Grant Date Fair Value, Vested	$0.32
Weighted Average Grant Date Fair Value, Forfeited	-142,334
Weighted Average Grant Date Fair Value, Non-vested options at December 31, 2014	$1.12

StockBased_Compensation_Detail4

Stock-Based Compensation (Details 4) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock [Member]
Stock Based Compensation [Line Items]
Number of Restricted Stock, Non-vested Balance Beginning	246,001	29,334	626,000
Weighted Average Issuance Price, Non-vested Balance Beginning	$2.64	$1	$0.71
Changes during the period:
Shares granted	0	325,000	109,748
Shares granted - Weighted Average Exercise Price		$2.86	$1
Shares vested	-137,667	-108,333	-529,330
Shares vested - Weighted Average Exercise Price	$2.46	$2.86	$0.76
Shares forfeited	0	0	-177,084
Shares forfeited - Weighted Average Exercise Price			$0.70
Number of Restricted Stock, Non-vested Balance Ending	108,334	246,001	29,334
Weighted Average Exercise Price, Non-vested Balance Ending	$2.86	$2.64	$1

StockBased_Compensation_Detail5

Stock-Based Compensation (Details Textual) (USD $)	12 Months Ended			3 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 12, 2010	19-May-10
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$17,103,045	$5,109,925	$82,270
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	12,738,143	2,789,901	62,410
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	3,391,030	254,779	15,600
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	657,500
Share-based Compensation	823,000	536,000	378,000
General and Administrative Expense [Member]
Stock Based Compensation Details [Line Items]
Allocated Share-based Compensation Expense	316,200	206,500	156,000
Director Stock Option Plan - 1999 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,975,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,369,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	807,782
Nineteen Ninety Nine Stock Incentive Plan [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,892,500
Percent FMV Common Stock Options Granted	100.00%
Plan 2009 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,473,748
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	230,420
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,004,334
Plan 1999 Plan 2009 And Director Plan [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,436,334
Common Stock, Capital Shares Reserved for Future Issuance	2,086,820
Maximum [Member] \| Director Stock Option Plan - 1999 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Maximum [Member] \| Nineteen Ninety Nine Stock Incentive Plan [Member]
Stock Based Compensation Details [Line Items]
Period From Date Of Grant	4 years
Minimum [Member] \| Director Stock Option Plan - 1999 [Member]
Stock Based Compensation Details [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Minimum [Member] \| Nineteen Ninety Nine Stock Incentive Plan [Member]
Stock Based Compensation Details [Line Items]
Period From Date Of Grant	1 year
Restricted Stock [Member]
Stock Based Compensation Details [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	114,200
Share-based Compensation	$507,000	$329,000	$222,000

Stock_Warrants_Details

Stock Warrants (Details) (Warrant [Member], USD $)	12 Months Ended
Stock Warrants (Details) (Warrant [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]
Stock Warrants [Abstract]
Beginning balance (in shares)	354,546	782,259	1,235,877
Beginning balance (in dollars per share)	$1.21	$0.85	$0.35
Stock warrants granted (in shares)	0	0	814,914
Stock warrants granted (in dollars per share)	$0	$0	$0.29
Stock warrants expired (in shares)	0	0	0
Stock warrants expired (in dollars per share)	$0	$0	$0
Stock warrants exercised (in shares)	-270,546	-427,713	-1,268,532
Stock warrants exercised (in dollars per share)	$1.21	$0.55	$0.01
Ending balance (in shares)	84,000	354,546	782,259
Ending balance (in dollars per share)	$1.21	$1.21	$0.85

Stock_Warrants_Details_Textual

Stock Warrants (Details Textual) (USD $)	Dec. 21, 2012	Dec. 08, 2010	Dec. 21, 2010	Dec. 31, 2012
Private Placement [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	387,201
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.01
First Placement Agent [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		338,182
Second Placement Agent [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		16,364
Warrant Issuedin Connection with Private Placement Offering [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1.21
Warrant Issued in Connection with Credit Agreement [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			881,331
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$0.01
Warrant Purchase Limit [Member]
Stock Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				427,713
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$0.55
Valueof Warrants Outstanding [Member]
Stock Warrants [Line Items]
Warrants and Rights Outstanding				$209,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current tax expense (benefit):
Federal	$97	$0	$0
State and local	76	-197	-184
Total current tax expense (benefit)	173	-197	-184
Deferred tax expense (benefit):
Federal	0	0	0
State and local	0	0	0
Total deferred tax expense (benefit)	0	0	0
Total income tax expense (benefit)	$173	($197)	($184)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Expected Statutory expense (benefit)	$1,844	($95)	($1,381)
Gain on derivative and amortization of debt discount	-693	0	0
Other non-deductible expenses	3	2	1
Change in valuation allowance	-1,031	30	1,317
Effective Income Tax Rate Reconciliation Sale Of New Jersey Net Operating Loss Carry Foward Amount	0	-197	-189
State income taxes, net of federal benefit	50	0
Federal tax impact of state tax benefit, net	0	63	68
Income Tax Expense (Benefit)	$173	($197)	($184)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Reserves and allowances	$40	$121
Other	647	161
Total current assets	687	282
Long Term Assets (Liabilities):
Property, plant and equipment basis difference	245	209
Net operating loss carry forwards	9,068	10,672
Tax credit carry forwards	293	217
Non-employee stock options	682	685
Other	-5	-3
Total Long Term Assets,net	10,283	11,780
Gross Deferred Tax Asset, net	10,970	12,062
Less Valuation Allowance	-10,970	-12,062
Deferred taxes, net	$0	$0

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Federal:
Operating Loss Carryforwards [Line Items]
Net operating losses	$26,602	$31,308
Research tax credits (expiring through 2025)	168	168
Alternative minimum tax credits/assessment (available without expiration)	123	28
State:
Operating Loss Carryforwards [Line Items]
Net operating losses	322	425
Alternative minimum tax credits/assessment (available without expiration)	$1	$21

Income_Taxes_Details_4

Income Taxes (Details 4) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$26,602
Year 2020 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	5,225
Year 2021 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,157
Year 2022 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	0
Year 2023 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,232
Year 2024 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	974
Year 2025 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,850
Year 2026 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,070
Year 2027 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	308
Year 2028 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	1,414
Year 2029 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	3,447
Year 2030 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	3,455
Year 2031 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	2,749
Year 2032 [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$3,721

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
Income Taxes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Income Tax Examination [Line Items]
Change in Ownership Percent	50.00%
Stockholder Ownership	5.00%
Income Tax Expense (Benefit)	$173,000	($197,000)	($184,000)
Proceeds From Sale Of Operating Loss Carry forwards		197,000	184,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Deferred Tax Assets, Valuation Allowance	10,970,000	12,062,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	1,100,000
Not Subject to Limitations [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards				8,500,000
Subject to Limitations [Member] \| Minimum [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards				1,000,000
Subject to Limitations [Member] \| Maximum [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards				2,300,000
Accounted for Additional Paid-in Capital [Member]
Income Tax Examination [Line Items]
Operating Loss Carryforwards	$2,400,000

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	Dec. 31, 2014
Years Ending December 31,
2015	$278,000
2016	418,000
2017	410,000
2018	348,000
2019	318,000
Thereafter	1,168,000
Total	$2,940,000

Lease_Commitments_Details_Text

Lease Commitments (Details Textual) (USD $)	12 Months Ended
Lease Commitments (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$216,200	$121,700	$66,900

Legal_and_US_Regulatory_Procee1

Legal and U.S. Regulatory Proceedings (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Legal and U.S. Regulatory Proceedings Details [Line Items]
Accrued Environmental Loss Contingencies, Current	$80,000
Restricted Cash and Cash Equivalents	54,000
Estimated Clean Up Costs [Member]
Legal and U.S. Regulatory Proceedings Details [Line Items]
Environmental Remediation Expense	$836,000

Employee_Benefits_Details_Text

Employee Benefits (Details Textual) (USD $)	12 Months Ended
Employee Benefits (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	100.00%
Defined Contribution Plan Minimum Annual Contribution Per Employee Percent	1.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$17,500	$17,500	$17,000
Defined Contribution Plan, Cost Recognized	126,600	93,000	71,000
Catchup Contribution Max [Member]
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$5,500
First Portion [Member]
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
First Portion [Member] \| Matching By Participants [Member]
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	3.00%
Second Portion [Member]
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Second Portion [Member] \| Matching By Participants [Member]
Note15 Employee Benefits Details [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	2.00%

2014_Public_Offering_Details_T

2014 Public Offering (Details Textual) (USD $)	12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 02, 2014	Jun. 27, 2014
Common stock, par value (in dollars per share)	$0.01	$0.01
Proceeds from Issuance of Common Stock (in dollars)	$24,858	$0	$0
Public Offering [Member]
Public Offering, Shares Authorized					4,650,000
Common stock, par value (in dollars per share)					$0.01
Share Price (in dollars per share)				$5	$5
Stock Issued During Period, Shares, New Issues				5,347,500
Proceeds from Issuance of Common Stock (in dollars)				$24,900
Public Offering [Member] \| Underwriter [Member]
Stock Issued During Period, Shares, New Issues	697,500

2012_Private_Placement_Former_1

2012 Private Placement - Former Related Party (Details Textual) (Private Placement [Member], USD $)	1 Months Ended
	Dec. 21, 2012
Private Placement [Member]
Proceeds from Issuance of Private Placement	$2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	387,201
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.01
Number of Years	10 years
Registration Statement Expected Deadline	six months
Registration Statement Declared Effective Months	9
Stock Issued During Period, Shares, New Issues	1,965,740

Asset_Purchase_Agreements_Deta

Asset Purchase Agreements (Details Textual) (USD $)	12 Months Ended
Asset Purchase Agreements (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Amortization of Acquisition Costs	$120,000	$60,000	$0
Prasco [Member]
Payments to Acquire Other Productive Assets	1,400,000
Milestone Payment	400,000
Payments to Acquire Productive Assets	1,800,000
Finite-Lived Intangible Asset, Useful Life	7 years
Amortization of Acquisition Costs	120,000
AstraZeneca [Member]
Payments to Acquire Other Productive Assets	500,000
Milestone Payment	6,000,000
Finite-Lived Intangible Asset, Useful Life	15 years
Business Combination, Contingent Consideration, Liability	3,000,000
AstraZeneca [Member] \| Royalty Obligations [Member]
Payments to Acquire Productive Assets	6,910,000
Valeant [Member]
Payments to Acquire Other Productive Assets	1,500,000
Payments to Acquire Productive Assets	2,048,000
Finite-Lived Intangible Asset, Useful Life	15 years
Valeant [Member] \| Option exercised for Each of Two Additional Products [Member]
Business Combination, Contingent Consideration, Liability	750,000
Valeant [Member] \| Option exercised for One Additional Products [Member]
Business Combination, Contingent Consideration, Liability	500,000
Valeant [Member] \| Option exercised for Total Aggregate Additional Products [Member]
Business Combination, Contingent Consideration, Liability	$2,000,000

Quarterly_Results_Details

Quarterly Results (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Total revenues, net	$13,736	$6,668	$6,483	$6,853	$6,726	$3,995	$3,820	$3,683	$33,740	$18,224	$8,563
Gross profit	8,391	2,632	2,903	2,866	2,579	1,311	1,147	1,108	16,792	6,145
Operating income (loss)	4,112	-144	-281	219	553	-42	-364	-229	3,906	-82	-3,136
Net income (loss)	5,631	-202	-345	167	671	-95	-403	-257	5,251	-84	-3,927
Net income (loss) attributable to common stockholders Â—basic	$5,631	($202)	($345)	$167	($637)	($95)	($403)	($257)	$5,251	($1,392)	($3,927)
Basic income (loss) per share	$0.11	$0	($0.01)	$0	($0.01)	$0	($0.01)	($0.01)	$0.11	($0.03)	($0.10)
Diluted income (loss) per share	$0.09	$0	($0.01)	$0	($0.01)	$0	($0.01)	($0.01)	$0.09	($0.03)	($0.10)

SCHEDULE_IIVALUATION_AND_QUALI1

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Valuation Allowance of Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Balance	$12,062	$12,358
Valuation Allowances and Reserves, Charged to Cost and Expense	0	0
Valuation Allowances and Reserves, Charged to Other Accounts	0	0
Valuation Allowances and Reserves, Deductions	-1,092	-296
Valuation Allowances and Reserves, Balance	10,970	12,062
Convertible Notes [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Balance	0
Valuation Allowances and Reserves, Charged to Cost and Expense	0
Valuation Allowances and Reserves, Charged to Other Accounts	43,700
Valuation Allowances and Reserves, Deductions	-2,300
Valuation Allowances and Reserves, Balance	$41,400